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vSummary
Today, cardiovascular disease remains the foremost cause of death worldwide. More
than 70% of all cardiovascular diseases are due to dysfunction of the coronary arter-
ies, which fail to supply sufficient oxygen to the heart. As first aid, the intravenous
injection of a vasodilatory drug improves the survival rate. The dose, however, is
limited because of side effects including a drop in blood pressure. Hence, a targeted
instead of a systemic delivery is highly desirable. Recently, mechano-responsive li-
posomes about 100 nm in diameter have been proposed to transport the drug to the
constrictions and preferentially release the vasodilator locally. In order to pave the
way for mechano-responsive nano-containers towards patient treatment, the present
thesis contains studies on (i) the morphology of a plaque-containing human coro-
nary artery throughout the preparation steps towards histology, (ii) the structural
alterations of the liposomes under selected flow conditions, and (iii) the immuno-
logical response of the drug-loaded liposomes in vitro and in vivo. High-resolution
hard X-ray tomography in absorption and phase contrast modes have shown that
paraffin embedding gives rise to an anisotropic shrinkage by 15 to 65% with respect
to formalin fixed tissues. The decalcification procedure compromises the determi-
nation of the lumen, leaving remaining components of the plaque abound in the
artery’s lumen. Consequently, the lumen should be extracted before decalcifica-
tion and paraffin embedding. For this purpose, phase tomography is much better
suited than the conventional attenuation-based approach because of the minor de-
pendence on the atomic number and the related reduction of streak artefacts. The
combination of spatially resolved small-angle X-ray scattering with microfluidics
allows for the measurement of mechanically induced morphological changes of lipo-
somes. Here, local changes in the average bilayer thickness and the mean size of
the mechano-responsive liposomes have been detected. Overall shape and bilayer
thickness do change already near the inlet to the constriction, but are dominant
near the outlet. At a flow rate of 0.2 µL/sec, the liposome’s bilayer thickness in-
creased by 30% compared to the thickness well before the constriction and under
static condition. The increase is in line with a mechanically induced loss of inter-
digitation between the phospholipid acyl chains. The immune response to dedicated
nitroglycerin-loaded, mechano-responsive liposomes has been quantified by means of
enzyme-linked immunosorbent assays in vitro and by monitoring the arterial pres-
sures in pigs in vivo. The research findings show comparable or less complement
activation than the Food-and-Drug-Administration-approved liposomal drugs Abel-
cet and Doxil. Even an up to three times human therapeutic dose does not increase
the pulmonary artery pressure and the systemic arterial pressure. The results of
the three subprojects demonstrate that physical approaches using smart containers
of nanometer size can establish a groundbreaking background for the translation of
basic science towards future patient treatments.
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Zusammenfassung
Herz-Kreislauf-Erkrankungen sind die weltweit am häufigsten auftretende Todes-
ursache. Mehr als 70% dieser Erkrankungen sind die Folge einer Fehlfunktion der
Herzkranzarterien, die das Herz nicht mehr mit genügend Sauerstoff versorgen kön-
nen. Um die Überlebenschancen im Notfall zu erhöhen, verabreicht man intravenös
gefässerweiternde Medikamente. Der Dosierung ist dabei aufgrund der auftretenden
Nebenwirkungen, einschliesslich Abfall des Blutdrucks, limitiert. Aus diesem Grund
ist eine gezielte statt der systemischen Wirkstofffreisetzung erforderlich. Mechano-
sensitive Liposomen mit einem Durchmesser von ungefähr 100 nm wurden unlängst
als Wirkstofffähren eingeführt, die den gefässerweiternden Wirkstoff bevorzugt an
der Verengung freisetzen. Um den Weg dieser mechano-sensitiven Wirkstofffähren
für die Behandlung von Patienten zu ebnen, umfasst die vorliegende Doktorarbeit
Studien über (i) die Morphologie von einem verkalkten menschlichen Herzkranzge-
fäss in der Abfolge der Präparationsprozesse für die Histologie, (ii) Formveränderun-
gen von Liposomen in ausgewählten Strömungsbedingungen und (iii) die Immunant-
wort auf wirkstoffbeladene Liposomen in vitro und in vivo. Hochauflösende Tomogra-
phie mit harten Röntgenstrahlen in Absorptions- und Phasenmodi hat aufgezeigt,
dass das Einbetten von einem verkalkten Herzkranzgefäss in Paraffin eine aniso-
trope Schrumpfung von 15 bis 65% gegenüber der Konservierung mittels Formalin
verursacht. Zudem beeinträchtigt eine Entkalkung die Vermessung des Lumen, weil
verbleibende Plaque-Komponenten die Arterie füllen. Deshalb sollte das Lumen vor
der Entkalkung bestimmt werden. Dazu eignet sich der Phasenkontrastmodus besser
als der konventionelle Absorptionskontrast, weil aufgrund der geringeren Ordnungs-
zahlabhängigkeit deutlich weniger Artefakte auftreten. Ortsaufgelöste Kleinwinkel-
röntgenstreuung in einem mikrofluidischen Kanalsystem, das ein Modell für ein ver-
engtes Herzkranzgefäss darstellt, erlaubt festzustellen, inwieweit die Strömungsver-
hältnisse in einer solchen Verengung die Morphologie der Liposomen beeinflusst.
Man kann hierbei die mittleren Dickenänderungen der Lipid-Doppelschicht und die
durchschnittlichen Grössenänderungen der Liposomen bestimmen. Die Form und
die Lipid-Doppelschicht der Liposomen ändert sich bereits vor der Verengung und
ist am Ende der Verengung besonders deutlich. Bei einem Durchfluss von 0.2µL/sec
wird die Lipid-Doppelschicht um bis zu 30% gegenüber dem statischen Zustand
grösser. Diese Zunahme der Dicke ist im Einklang mit dem Verlust der Verzahnung
zwischen den Alkylketten der Lipide in der Doppelschicht. Die Immunantwort ge-
genüber gezielt mit Nitroglyzerin beladenen, mechano-sensitiven Liposomen wurde
mittels Enzym-gebundener Immunosorbent-Assays in vitro und durch Messung der
Gefässinnendrücke in Schweinen in vivo quantifiziert. Die Ergebnisse zeigen gegen-
über etablierten Liposom-basierten Medikamenten (Abelcet, Doxil) eine vergleichba-
re oder geringere Komplementaktivierung. Sogar eine gegenüber der heute verwen-
deten dreimal höhere Dosis erhöht den Gefässinnendruck der Pulmonalarterie nicht.
Die Ergebnisse der drei Teilprojekte veranschaulichen, dass physikalische Ansätze
für die Nutzung von intelligenten Nano-Wirkstofffähren wegweisende Hinweise für
viii
weitere Entwicklungen vor dem Hintergrund einer zukünftigen Patientenbehandlung
schaffen können.
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11 Introduction
Myocardial infarction, also known as heart attack, is often caused by cardiovascular
diseases and is responsible for about 7.4 million deaths every year [1]. Myocardial
infarction is caused by coronary artery dysfunctions leading to the accumulation of
white blood cells and the formation of fibro-fatty tissues, namely plaque, within the
artery. Plaque is responsible for narrowing the artery. When the plaque ruptures,
the blood clot forms which prevents blood supply to the heart muscle, causing heart
attack. In emergency situations, one of the conventional protocol utilized to aid the
patient includes the intravenous injection of a vasodilator, such as nitroglycerin, to
widen the occluded arteries. Nitroglycerin injection allows blood perfusion to the
heart, but its systemic administration leads to the decrease of peripheral vascular
resistance with a consequent fall in blood pressure. The obstruction of the artery is
responsible of a significant increase of the arterial flow velocity in diseased regions
of the blood vessel compared to healthy ones [2]. Indeed, one can take advantage of
the differences in the blood velocity to release the drug locally, using a purely phys-
ical trigger. In this scenario, a smart drug delivery at the obstruction site would be
beneficial. Drug delivery systems concern all methods developed for administration
of a pharmaceutical compound with therapeutic effect. Nanometer-sized materials,
are suitable for developing drug delivery systems, as they cross organs and tissues.
A drug delivery system can be fabricated using inorganic materials such as gold, iron
oxide, or silica; organic polymers such as polystyrene (PS), polylactic acid (PLA),
or poly(lactic-co-glycolic acid) (PLGA); or biopolymers such as proteins, carbohy-
drates, or phospholipids utilized to prepare liposomes. The use of liposomes as
drug delivery vehicles is widespread. About twelve FDA-approved liposomal drugs
are nowadays in clinical use [3]. Recently discovered artifical phospholipid-based
shear-responsive nano-containers, namely Pad-PC-Pad, [4] are valuable candidates
for releasing the drug at obstructed regions of arteries.
To improve the mechano-sensitivity of these liposomes a deep knowledge of the
artery morphology including plaque structure and lumen area is essential. It would
allow better understanding of the local shear stress changes at the site of the oc-
clusion. The effect of the local shear stress on the nano-containers should then be
investigated using suitable system, which can emulate a diseased blood vessel. De-
spite the clinical benefit of nano-carriers in targeted drug delivery, liposomal drugs
are often recognized as foreign objects and hence are attacked by the immune sys-
tem. Therefore, in vitro and in vivo assessments as a preclinical immune toxicity
test is mandatory in the development of drug delivery systems.
2 1 Introduction
1.1 Micro computed tomography for the determination of
constricted arteries morphology
The understanding of human coronary artery diseases initiation and progression is
often focused on the comprehension of the vessel dimensions, the plaque composition
[5], as well as the detection of vulnerable plaque, the evaluation of thrombus, and
the identification of neointima formation [6]. Another branch of interest in the
investigation of cardiovascular disorders includes the assessment of coronary arteries
morphology. The narrowing of the arteries leads to an increase of the vessel wall
shear stress values at least one order of magnitude with respect to healthy blood
vessels [7]. Proof-of-concept studies based on vasodilatory and thrombolytic drug
release towards shear-activated nanoparticles based on phosphatidylcholine (PC)-
based nano capsules [8], artificial phospholipids-based liposomes [4], and copolymers
[9] have been reported. In order to tune the release of the drug by nano-containers,
the shear stress parameters of both diseases and healthy regions of the coronary
arteries are required.
Imaging techniques such as coronary computed tomography angiography and mag-
netic resonance are widely used as in vivo methods for the visualization and char-
acterization of coronary artery occlusions. Although these techniques guarantee
information on the physiological conditions of the coronary artery, they present lim-
itation in terms of three dimensional evaluation of blood vessel anatomy [10], and
do not reach the micrometer resolution, which is necessary for quantitative blood
flow simulations.
Histology is considered the standard of reference for the ex vivo visualization and
characterization of biological tissues down to sub-micrometer scale. However, it has
been stated that histological imaging does not show the native morphology of the
specimen [11]. On the contrary, X-ray micro computed tomography (µCT) is a well
established imaging method allowing for non-destructive and three-dimensional (3D)
rendering of biological specimens, including brain [12,13], nerves [14], cartilages [15]
and coronary arteries [16, 17]. The visualization of diseased coronary arteries by
means of µCT can elucidate the effect of the preparation steps for histology with
respect to the artery morphology.
In section 2.1 we evaluate how the morphology of a segment cut from a plaque-
containing human coronary artery is affected by formalin fixation, paraffin embed-
ding, and decalcification which preludes the histological sectioning.
A diseased artery contains both high and low X-ray absorbing tissues, e.g. plaque
and lumen, respectively. Therefore, conventional absorption µCT, which probes
the imaginary part β of the refractive index n = 1 − δ + iβ, is not suited for the
visualization of these specimens. Phase contrast µCT techniques, which are sensitive
to phase shift of the X-rays passing through the specimen, and thus to the real part
δ of the index of refraction, is better suited for these specimens. This is because δ
varies less than β between the high- and low-absorbing tissues and thus the dynamic
range of the phase contrast measurement is sufficient for simultaneous visualization.
Herein, 3D tomography data of the calcified artery are acquired in phase contrast-
mode, whereas scans of the decalcified artery are carried out in absorption contrast-
mode.
The lumen cross section along the centerline is determined. For extracting the
centerline a dedicated pipeline is implemented.
3The results indicate that the lumen cross section obtained from the tomography
data of the artery after formalin fixation allows for the determination of the plaque
position along the artery. In contrast, paraffin embedding has a strong impact on
the morphology of the artery lumen. The decalcification step damages internal and
external regions of the artery, hampering the lumen segmentation. Furthermore, a
comparison between tomography data acquired with advanced laboratory- and syn-
chrotron radiation sources indicate that the use of a table-top tomography system
is reasonable for the assessment of the artery lumen morphology.
The evaluation of the morphology of diseased arteries is the basis for blood flow
simulations. Blood flow simulations provide the vessel wall shear stress values at
both healthy and diseased regions of the artery [18]. The knowledge of the wall
shear stress range is essential for the optimization of the mechanical properties
of mechano-responsive liposomes. Consequently, it is advisable to investigate how
the shear-responsive Pad-PC-Pad liposomes behave when subjected to an external
perturbation, such as a shear stress gradient.
1.2 Shear-responsive liposomes investigated by means of
microfluidics and small-angle X-ray scattering
Liposomes are made out of amphipathic molecules, which comprise a hydrophilic
head and a hydrophobic tail. In aqueous solution, they assemble forming a closed
phospholipid bilayer. Liposomes were described for the first time by Bangham and
co-workers in 1965 [19] and soon suggested as drug delivery systems [20].
The artificial 1,3-diaminophospholipid, namely Pad-PC-Pad (nomenclature in Fe-
dotenko et al. [21]) forms faceted liposomes [4, 22–24]. Pad-PC-Pad with a mean
diameter of about 100 nm are produced here using the well established extrusion
method [25].
The unusual shape of these liposomes can be regarded as an intermediate state of
minimized energy between a spherical and a planar surface [26]. Under mechanical
stimulation, the attenuation of the defects present in the membrane of Pad-PC-Pad
liposomes might be responsible for their mechanosensitive properties. At constricted
blood vessels, the blood velocity, and therefore the shear stress, is significantly in-
creased. This enhanced shear stress can trigger the release of the drug carried by
Pad-PC-Pad liposomes.
Hence, an in vitro model to test the behavior of Pad-PC-Pad under a shear stress
gradient would be beneficial. Herein, microfluidics with a suitable design has been
utilized allowing for the investigation of the liposomes under dynamic conditions.
To probe the structural modifications of the liposomes while spatial and temporal
conditions change, small-angle X-ray scattering (SAXS) has been combined with mi-
crofluidics. SAXS is based on the elastic scattering of the X-rays traveling through
the sample. The scattered intensity I is collected as a function of the scattering
vector q, which depends on the scattering angle θ as q = 4pi sin(θ)/λ, being λ the
X-rays wavelength.
In section 2.2, a microfluidic system which aims mimicking the geometry of a con-
stricted blood vessels is reported. The microfluidic system consists of a micrometer-
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sized rectangular channel with an abrupt constriction in the middle. The channel,
connected to a syringe pump system, allows tuning the flow rate, and thus the shear
rate within the microfluidic device. Computational fluid dynamic simulations help
to predict the profile of the velocity and the shear rate along the microfluidic device.
Preliminary SAXS measurements to test the accessibility of the SAXS signal of the
liposomes are performed in boron silicate glass capillary and in microfluidic devices.
The results indicate that, despite liposome suspensions provide low contrast (lipid
concentration of about 20mg/mL), microfluidics and SAXS is a challenging but
promising approach for probing these mechano-sensitive liposomes in vitro.
In section 2.3, the behavior of shear-sensitive liposomes Pad-PC-Pad by tuning
the flow conditions within a microfluidic device is investigated. Two dimensional
spatially resolved maps reveal the local variations of the scattering signal and guide
the selection of regions within the device. In these regions, the scattering signal is
radially integrated providing the scattering intensity I as a function of the scattering
vector q at different flow velocities. The results show that under dynamic conditions,
Pad-PC-Pad liposomes’ structure is sensitive at different length scales.
Pad-PC-Pad liposomes’ behavior under flow conditions is compared to liposomes
prepared using dipalmitoylphosphatidylcholine (DPPC), which do not show any
significant response.
These findings make Pad-PC-Pad liposomes promising as drug delivery system for
targeting constricted blood vessels. However, the intravenous administration of
liposomal drugs might cause adverse reactions of the immune system. Therefore, in
vitro and in vivo immunological tests with the liposomes are required.
1.3 Immune toxicity tests with shear-responsive liposomes
Over almost five decades, researchers have improved liposome properties in terms
of drug loading, rapid clearance, triggered release and transport of substances.
This progress has supported the idea of using liposomes as vehicles of anti-cancer
[27], anti-fungal [28], anti-biotic [29] and anti-inflammatory drugs.
Despite the advantages mentioned above, liposomes are often recognized as foreign
by the body due to their morphology and size [30] and, thus, can trigger the im-
mune system which responds activating a biochemical cascade, named complement
activation. The complement system [31] is responsible for attacking and destroying
the suspected substance. Nevertheless, it might give rise to adverse immune reac-
tions named complement activation-related pseudo-allergy (CARPA). CARPA has
been widely used to describe mild to severe hypersensitivity reactions [32] in up to
45% of the patients [33]. These immune system reactions leads to abrupt variations
of hemodynamic parameters including the pulmonary artery pressure and in the
systemic arterial pressure which can be fatal for patients affected by cardiovascular
pathologies. Liposomal drugs that cause adverse reaction of the immune system
have been previously reported [32].
Hence, in vitro and in vivo assessments of CARPA, as a preclinical immune toxicity
test in the development of liposomal drugs, are recommended.
Szebeni and co-workers have shown that among the main factors causing in vitro
complement activation by liposomes are the inhomogeneity in size and lipid formu-
lation, the presence of poly-ethylene glycol (PEG), the polyamino coating, and the
5cholesterol in the bilayer membrane [30].
In section 2.4, an in vitro and in vivo study on the immunological response towards
Pad-PC-Pad liposomes is reported.
Pad-PC-Pad liposomes concentrated and ten-fold diluted, with and without PEG,
bare and loaded with nitroglycerin were incubated with human and porcine sera
(in vitro assessments). Furthermore, the sera were incubated with saline (liposome
buffer) and nitroglycerin (liposome cargo) used as negative controls as well as with
Doxil, Abelcet (Food and Drug Adiministration-approved liposomal drugs) and zy-
mosan as positive controls.
During the in vitro test, the three complement pathways through which the com-
plement cascade might activate and the final branch of the cascade, are detected by
measuring the increased level of dedicated proteins of the complement system.
The in vitro results allow us to state that i) the alternative pathway might acti-
vate the complement activation in presence of concentrate Pad-PC-Pad suspension
containing both PEG and nitroglycerin, in agreement with the literature [34]; ii)
diluted Pad-PC-Pad liposomes show comparable level of complement activation as
reported for Doxil [35]. The in vitro findings are supported by the in vivo experi-
ment indicating that Pad-PC-Pad liposomes loaded with a drug dosage up to three
times the human therapeutic dose yield no significant changes in the continuously
monitored hemodynamic parameters.
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ABSTRACT
Atherosclerotic arteries exhibit characteristic constrictions and substantial deviations from cylindrical shape. Therefore,
determining the artery’s cross-section along the centerline is challenging, although high-resolution isotropic three-dimensional
data are available. Herein, we apply high-resolution computed tomography in absorption and phase to a plaque-containing
human artery post-mortem, through the course of the preparation stages for histology. We identify the impact of paraffin
embedding and decalcification on the artery lumen. For automatic extraction of lumen’s cross-section along centerline we
present a dedicated pipeline. Comparing fixated tissue before and after paraffin embedding gives rise to shape changes
with lumen reduction to 50-80%. The histological slicing induces further deformations with respect to tomography. Data
acquired after decalcification show debris unintentionally distributed within the vessel preventing the reliable automatic lumen
segmentation. Comparing tomography of laboratory- and synchrotron-radiation-based X rays by means of joint histogram
analysis leads us to conclude that advanced desktop tomography is capable of quantifying the artery’s lumen as an essential
input for blood flow simulations. The results indicate that the most reliable lumen quantification is achieved by imaging the
non-decalcified specimen fixed in formalin, using phase contrast modality and a dedicated processing pipeline. The results
presented will initiate further studies on pathological cases.
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Introduction
Blood vessels are commonly represented as a network of hollow tubes that transport blood through the human body. In a
healthy situation, hemodynamics is characterized by a laminar flow and a wall shear stress in the order of 1 Pa1. Constrictions,
for example as the result of atherosclerosis, give rise to a wall shear stress increased by at least one order of magnitude2. Recent
communications have proposed exploiting increased wall shear stress for the targeted delivery of vasodilatory drugs3, 4. For
the clinical use, however, the threshold for drug release has to be determined. Consequently, the morphology of the vessel
lumen in both healthy and diseased conditions has to be evaluated. In vivo imaging techniques such as coronary computed
tomography angiography and magnetic resonance imaging are used widely for the visualization and quantification of coronary
artery occlusions. Although these techniques yield information under physiological conditions, they are limited in terms of the
three-dimensional evaluation of blood vessel anatomy5, and they do not reach the micrometer precision required for meaningful
flow simulations6. Therefore, researchers have applied expensive and time-consuming serial sectioning and the combination
of two-dimensional micrographs7. This histological approach, however, relies on extended tissue preparation procedures,
namely fixation, decalcification, embedding, and staining, which substantially modify the geometry of the vessel with respect
to the in vivo situation. In order to reduce or correct the impact of the numerous preparation steps, and to achieve isotropic
spatial resolution, several research teams have recently applied micro computed tomography (µCT)8–12. Using the conventional
attenuation contrast, the plaque present in atherosclerotic vessels dominates X-ray absorption6. Typically, only the plaque
becomes visible, whereas the vessel wall is almost transparent. Using reduced photon energies, the highly absorbing plaque
causes severe streak artefacts, and the visualization of the vessel wall is compromised. Therefore, it is beneficial to use phase
contrast, including X-ray grating-based interferometry (XGI)13.
In the present communication, we report on µCT measurements of a diseased human artery segment subsequent to individual
tissue preparation steps, i.e. formalin fixation, paraffin embedding, and decalcification. The tomography data were registered
in order to determine local geometrical modifications. The lumen was segmented and the cross-section along the centerline
derived. It should be noted that determining the centerline is a demanding undertaking because of the specific morphology in the
constriction, and thus the convergence of widely used approaches is not guaranteed. In fact, most of the present approaches14–16
follow points with the greatest distance to the surface, and they can abruptly change sites, leading to undesired jumps in the
centerline. Thus, a robust iterative procedure for lumen quantification is proposed herein, dedicated to large deviations from
the classic cylindrical shape, allowing the comparison of the lumen cross sections of the artery segment obtained at each of
the tissue preparation steps to histology. The application of advanced methologies in the present study allow for a precise
evaluation of a segment of a stenosed vessel lumen in three dimensions revealing the impact of the preparation procedure.
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Results
Artery imaging and lumen segmentation
Table 1 details specimen preparation and the imaging parameters used. The images in Fig. 1a show a CT slice from Dataset #1
on the left, with its counterpart from Dataset #2 on the right. The counterpart slice was identified by the three-dimensional affine
registration of Datasets #1 and #217. The similarity of the anatomical structures is elucidated best by the plaque, represented
by a black to yellow color. Formalin fixation led to a dominant artefact, namely the dark area within the vessel wall, caused
by the presence of gas bubbles within the artery lumen, as displayed in the left image of Fig. 1a. On the other hand, paraffin
embedding resulted in cracks within the plaque and air inclusions within the soft tissue, associated with streak artefacts (see Fig.
1a, right). A direct comparison of the diseased artery before and after paraffin embedding clearly indicates that only the plaque
is preserved in size and shape, and the soft tissues substantially deform in a non-isotropic manner.
The image in Fig. 1b on the right displays a slice selected from the CT Dataset #3A obtained from the decalcified artery.
The decalcification process substantially reduces the plaque, in which case streak artefacts are prevented. However, additional
morphology modifications are present, including damage to the inner and outer (data not shown) parts of the vessel wall. Lumen
segmentation failed where damage of the vessel wall was present. For comparison, the related slice from absorption-contrast
data, i.e. Dataset #3B—see left part of Fig. 1b—with around two times worse spatial resolution is displayed. Likewise, this
image indicates that the lumen cannot be segmented by means of the presently available automatic procedures.
The gradients in intensity and the large deviation from the cylindrical shape prevent the successful lumen segmentation by means
of Frangi filtering18, which is widely employed as vessel detector in 3D imaging. In order to determine cross-section along the
artery, the lumen has been identified in undamaged parts, involving user interactions (cf. Methods, Lumen segmentation). We
proposed a dedicated iterative procedure (cf. Fig. 10) to extract the centerline perpendicular to the cross-sections of successfully
segmented lumen.
The centerline found after the first four (i = 1, 2, 3, 4) and the eighth (i = 8) iterations for the segmented lumen of Dataset
#1 are shown in 2a.
Fig. 2b displays the centerline plotted within the corresponding artery lumen, oriented as in Fig. 2a (Fig. 2b, left), and
rotated by 90◦ (Fig. 2b, right). The appendage shown in Fig. 2b left, represents a bifurcation present along the artery. Due to
the artery bifurcation, the centerline i = 1, a dark blue-colored curve, exhibits a bulge that disappears at iteration i = 8, a light
green-colored curve, where the condition ρ < µ is reached (µ = 0.3 voxel). Convergence of the residual ρ for Dataset #1 is
represented in Fig. 2c.
Fig. 3 shows the cross-sectional areas of Datasets #1 (black dots) and #2 (red dots) obtained as described in Methods section.
The procedure was successfully applied to Dataset #1 for a length of approximately 15 mm out of 20 mm. The remaining
artery of 5 mm length suffered from strong intensity gradients. Furthermore, the intensity gradient (see Fig. 1a, left) strongly
affected lumen segmentation in the region between 8 and 10 mm. In Dataset #2, the artery could be segmented with success at
a length of 9 mm that remained undamaged after paraffin embedding. The lower diagram in Fig. 3 shows the shrinkage of the
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artery as a function of the position along the centerline, whereby paraffin embedding caused a reduction in the cross-sectional
area by values between about 15% and 65%. The diagram in Fig. 4 shows the results of the cross-sectional areas of Datasets
#3A (orange dots) and #3B (blue dots). The two Dataset #3A and #3B are acquired from the same specimen measured using
synchrotron radiation and conventional source in absorption contrast, respectively.
The comparison demonstrates that the data provide reliable values in a restricted part of the sample, namely from 1.2 to
2.6 mm. From position 2.6 to 4.5 mm (black dashed line), the cross-section of Dataset #3B was affected by 20-voxel-wide
erosion/dilation, as a consequence of the results provided by lumen segmentation. From position 4.5 to 5.6 mm (red-colored
dashed line), the cross-section obtained from Dataset #3A was affected by artefacts, which give rise to an overestimation of the
cross-sectional area.
Laboratory-based µCT vs. synchrotron-radiation-based µCT imaging
Fig. 5 is a bivariate representation of the histograms from the registered Datasets #3A (bottom, left) and #3B (top, right). This
joint histogram contains four clusters, each corresponding to the embedding material (paraffin), the fibrous tissue, the vessel
wall, and the residual plaque, respectively. In both histograms, the paraffin (red-colored Gaussian peak) is clearly present and
segmentable. It is, however, broader in the histogram of the Dataset #3A than in the histogram of Dataset #3B. The histogram
of Dataset #3B distinguishes, in addition to the paraffin, between fibrous tissue (green-colored Gaussian peak), tissues forming
the vessel wall (dark blue-colored Gaussian peak), and the remaining calcification (light blue-colored Gaussian peak), whereas
the histogram of Dataset #3A displays a broad peak (gray-colored Gaussian peak). After filtering Dataset #3A using a Gaussian
with σ = 2, the peaks in the histogram also exhibit the four Gaussian peaks, as exemplified in Fig. 6 bottom left.
Complementarity of tomographic imaging to histology
Fig. 7 contains optical micrographs of three histological slices (left), which were stained using H&E, Miller, and Masson’s
Trichrome. The corresponding CT-slices (right) from the Dataset #3A were selected on the basis of slice-to-volume registration19.
On the images of the histological sections (Fig. 7, left), one finds the adventitial tissue on the outer part of the vessel wall.
Muscular media is stained red-brown on H&E, gray on Miller and red-blue on Masson’s Trichrome. Asymmetric decalcified
plaque is visible on the left side of the artery. The artefacts caused by histological slicing are clearly visible, if one compares
them with the tomography data. The artery walls, and especially the region where the decalcified plaque is present, are
deformed.
Discussion
In order to visualize simultaneously lower and higher X-ray absorbing tissues in the diseased artery (Fig. 1a), phase contrast
is better suited than absorption, due to the dependence of phase and absorption on the atomic number20. Thus, the plaque-
containing artery segment was visualized with a phase contrast modality. Nevertheless, the high phaseshift of the plaque still
gives rise to sporadic streak artefacts as clearly present in Datasets #1 and #2, cf. Fig. 1a.
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It has been reported that formalin fixation causes tissue shrinkage of about 3−6%21. In the brain, formalin fixation gives
rise to local strains as large as 15%22. Therefore, one can reasonably assume that the derived lumen of the artery segment
will be smaller than in the in vivo situation. Highly intense hard X-rays often induce the formation and growth of air bubbles,
especially at internal interfaces23, which are found within the vessel walls (cf. Dataset #1), causing severe changes in the ∆δ
values.
Air bubble formation is circumvented by paraffin embedding, albeit this does lead to streak artefacts caused by cracks in the
plaque and entrapped air in the soft tissue during the embedding process. H. J. Gundersen et al. have reported that dehydration,
owing to paraffin embedding, can result in shrinkage of up to 30%24. In fact, the data represented in Fig. 1a confirms that
paraffin embedding causes drastic deformation and shrinkage of the soft tissues while the morphology of the plaque remains
unaffected.
The streak artefacts herein vanished as the result of the decalcification (cf. Fig. 1b), although lumen segmentation was
hampered, as remains of the decalcified plaque infiltrated the lumen (data not shown). The morphology of the diseased part of
the artery could therefore not be reliably quantified.
In order to investigate the impact of the individual tissue preparation steps, namely formalin-fixation, paraffin embedding
and decalcification, the cross-sectional area along the artery lumen has to be determined. Since the artery cannot be reasonably
described as a cylinder, its lumen was not parallel to the z-axis. Determining the center of each CT-slice is insufficient for
extracting the centerline. Approaches reported in the literature, including piece-wise linear curves14 and B-splines15, 16, are
successful only to a limited extent due to the challenging geometry. Hence, it was necessary to search for alternative ways
to extract the centerline along the bent and bifurcated diseased artery. The proposed algorithm revealed strong convergence.
Application of the algorithm to the individual datasets indicates that the number of iterations depends not only on deviation
from the cylindrical shape but also on the specimen preparation. For the Datasets #2 and #3A, the number of iterations was four
and five, to reach a residual of less than 0.3 voxel, respectively, whereas for the Dataset #1 the artery bifurcation increased the
number of iterations to eight (see Fig. 2). Dataset #3B contained some tissue debris in the segmented lumen, resulting after
the decalcification process. This dataset was subjected to 20 voxel-wide erosion/dilation. The number of iterations to reach
convergence increased to 29.
If one assumes that tissue shrinkage owing to formalin fixation is below 10%, as reported by Zehbe et al.21, the plot of the
cross-section along the centerline for Dataset #1 (Fig. 3, black dots) should yield the information on the artery lumen which
reduces due to the formation of the plaque within the vessel wall. Contrary to formalin fixation, embedding the specimen in
paraffin required substantial handling by the user, leading to deformation which influenced the morphology of the specimen,
and thus the lumen cross section (cf. Fig. 3, red dots). In particular, the artery segment was embedded, de-embedded and
re-embedded several times before obtaining a paraffin block without air bubbles entrapped.
The histogram data for the synchrotron radiation source does not allow distinguishing the information on the fibrous tissue,
the vessel walls and the remaining plaque, which is instead possible observing the histogram data from the conventional X-ray
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source. As the filtering of the data acquired at the synchrotron radiation source highlights the peaks, the authors suspect that the
proprietary Bruker reconstruction software contains a similar filtering feature. Therefore, one may hypothesize that filtering
more effectively improves contrast than binning25. The main deduction from the joint histogram analysis is the almost linear
correspondence of attenuation values obtained from Bruker and synchrotron, which implies that the conventional approach and
the synchrotron radiation µCT shows comparable density resolution. Each modality gives rise to four components, namely the
vessel wall, the fibrous tissue, the remaining plaque, and the embedding material (paraffin).
To validate the tomography data, histology is required. In the current literature, it has been claimed that with respect to
H&E and Miller, Masson’s Trichrome staining is the better choice for comparing histology with tomography data6. In the
present study, no significant differences in terms of tissues identification could be found, so the arbitrary selection of one
staining protocol was enough to validate the morphological findings from hard X-ray tomography. Although the features are
co-resident in tomography and histology, one recognizes some additional deformations owing to cutting. These additional
deformations can be seen better by the clipped slices displayed in Fig. 8.
Precise determination of the lumen from a plaque-containing human artery remains a subject for further research, since (i)
in vivo methods do not reach the necessary micrometer resolution, (ii) the post-mortem evaluation using hard X-rays is not only
suboptimal because formalin fixation results in moderate shrinkage, but also because it often induces bubble formation and
growth during the data acquisition, (iii) when embedding the diseased artery into paraffin, bubble formation and growth can be
prevented at the expense of massive local deformations, (iv) decalcification prevents the occurrence of streak artefacts, but often
also induces tissue damage, which seriously compromises lumen extraction, and (v) the histological sections of decalcified
arteries hardly represent the artery’s morphology in vivo.
In conclusion, the present study proposes that the lumen from a plaque-containing artery should be based on formalin
fixation and hard X-ray imaging. The formation and growth of gas bubbles in the formalin-fixed specimen can be reduced
by using less intense X-ray beams with a photon energy as high as possible and adapted protocols for preparing the formalin
solution and the tissue. Future research activities may include besides a reduction of imaging and preparations artefacts, a
generalization of the proposed processing pipeline for further biomedical applications.
Methods
Specimen preparation
A 2.2-cm-long segment of a plaque-containing human coronary artery from the distal part of the anterior interventricular artery
was explanted post-mortem from a female patient. Ante-mortem she consented to give her body for research purposes to the
medical faculty of Lausanne University, Switzerland, the forensic department of which is a joint venture with the neighboring
University of Geneva. Ethical approval for this study (Ethical Committee N◦ NAC 09-105) was provided by the Ethical
Committee N.A.C. (Neuclid, Apsic, Chirurgie, Pathologie, Radiologie) of Geneva University Hospitals, Geneva. All methods
were performed in accordance with relevant guidelines and regulations.
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The artery segment was placed in a 2.0 mL Eppendorf tube and fixed with 4% paraformaldehyde (PFA). After imaging at
the synchrotron radiation facility, the segment was embedded in paraffin. Prior to paraffin embedding, the surrounding tissues,
mainly fatty tissue, were removed from the artery. To minimize the specimen diameter, the paraffin block was trimmed with a
scalpel.
Later, the segment was de-embedded and then subjected to decalcification. The segment, fixed in 4% paraformaldehyde
(PFA) for two days, was immersed in a decalcifying solution (87 vol% distilled water, 8 vol% formic acid, 5 vol% PFA) at a
temperature of 37 ◦C. Decalcification was stopped when the decalcifying solution did not become white after mixing with 1 mL
ammoniumoxalate (5%, vol/vol) and 1 mL ammonia (5%, vol/vol). Subsequently, the specimen was immersed in alcohol 70%
for a period of five hours, dehydrated, embedded in paraffin at a temperature of 60 ◦C, and cooled down to room temperature.
Multimodal imaging of a plaque-containing human coronary artery
For simultaneous visualization of the highly X-ray absorbing plaque and the surrounding soft tissues, the human coronary
artery segment was imaged using XGI-based µCT at the beamline P07 (PETRA III, DESY, Hamburg, Germany) once without
and once with paraffin embedding. After decalcification and re-embedding into paraffin, the segment was visualized using
the absorption-contrast-based tomography setup at the beamline P05 (PETRA III, DESY, Hamburg, Germany) and using the
laboratory-based tomography system Skyscan 1275 (Bruker, Kontich, Belgium). Table 1 summarizes the preparation of the
human artery segment and the parameters employed for data acquisition.
Laboratory-based tomography
Radiographs were recorded using a 3 Megapixel (1944 × 1536) CMOS camera featuring a pixel size of 75 µm. In total, 1200
projections (rotation angle increment of 0.3◦) of the specimen were collected using an acceleration voltage of 15 kV and a
beam current of 156 µA. Exposure time was set to 2.3 s. Effective pixel length corresponded to 5.2 µm. The tomograms were
reconstructed using the manufacturer’s software NRrecon, in which the Feldkamp algorithm26 is implemented.
Synchrotron radiation-based double-grating interferometry
The P07 beamline is operated by Helmholtz-Zentrum Geesthacht, Germany. For phase imaging, the specimen was placed in a
water bath to reduce artefacts owing to large X-ray wave front curvature at the specimen background interface, commonly
referred to as “phase-wrapping” artefacts. As the size of the artery exceeded the field of view, it was moved vertically to the
X-ray beam in 10 and 13 height steps for the formalin-fixated and paraffin-embedded states, respectively. Radiographic data
were acquired at a photon energy of 45 keV. The double-crystal Si(111) monochromator (horizontal Laue geometry) was bent
to match Rowland circle geometry. The beam-splitter grating (4.8 µm periodicity, Ni) was placed 31.4 cm away from the
analyzer grating (2.4 µm periodicity, Au), corresponding to the third fractional Talbot order. The detection unit contained a 100
µm-thick CdWO4 scintillator. The obtained optical image was magnified 5× and recorded by a CMOS camera, which was
developed and produced at the Institute for Data Processing and Electronics (Institute of Technology, Karlsruhe, Germany) and
uses a chip (CMOSIS, Antwerp, Belgium) with 20 megapixels (5120 × 3840) each 6.4 µm in size. The effective pixel length
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corresponded to 1.3 µm. For the formalin-fixed specimen, 900 projections were recorded over 360◦, using an asymmetric
rotation axis configuration, whereas 1200 projections were acquired for the paraffin-embedded specimen. At each angle, four
phase-step images were taken over one period of the interference pattern. The exposure time was set to 0.2 s per phase step
image. Prior to reconstruction, the phase tomograms were binned by factors of 2, 4, and 8 to simplify their handling and to
improve the contrast25. After binning, phase-retrieval was performed by means of pixel-wise Fourier analysis. In order to
reconstruct the phase tomograms, the differential data were integrated and then treated like attenuation-based data.
Synchrotron radiation-based tomography in absorption-contrast mode
The undulator source combined with the double-crystal monochromator, consisting of two Si(111) Bragg crystals, provided
photons with an energy of 10 keV at the HZG beamline P05. The X-ray photons were converted into an optical image by
a 100 µm-thick CdWO4 scintillator and recorded by a camera (SciCam series) with a Kodak CCD chip KAF-09000 (3056
× 3056) comprising of 12 µm-wide pixels. The specimen-detector distance was set to 10 mm. In all, 1200 equiangular
radiographs with an effective pixel length of 2.4 µm were recorded along 180◦, with an exposure time of 1.5 s per projection.
Prior to reconstruction, the projections were binned by a factor of two. The tomograms were obtained by the standard filtered
back-projection algorithm.
Lumen segmentation
The lumen of the artery was determined from the tomography data, by means of the region-growing tool available in VG Studio
MAX 2.1 (Volume Graphics GmbH, Heidelberg, Germany). Prior to this segmentation procedure, the data were smoothed
using a median filter with a kernel size of 15. In order to visualize the impact of the filter, the segmented lumen cross section of
all the CT-slices of Dataset #2 were compared before and after filtering (cf. Fig. 9, where lumen area of hundred CT-slices are
shown). As the median filter caused slight and constant lumen enlargement over all the CT-slides, the lumen was eroded by one
voxel. In case of Dataset #3B the segmented lumen was eroded/dilated by 20 voxels.
Cross section along the centerline determined from the segmented lumen
For the datasets listed in Table 1, the centerline of the artery segment was calculated. The individual steps in the iterative
procedure used herein are represented in Fig. 10. The main steps are as follows:
1. Initialization. In the initialization step, the binarized data for the segmented artery lumen were loaded as a stack of 2D
slices in the x− y-plane and stored as a 3D volume with isotropic resolution in the x-, y-, and z directions. The z-axis was
oriented parallel to the artery.
2. Compute centerline c0,k along the z-axis. The centerline is discretized on points c0,k with k = 1,...,Nk, where Nk is the
number of x− y-slices. The points c0,k correspond to the geometrical centers of the lumen for each slice orthogonal to
the z-axis, and the resulting centerline c0,k is smoothed using a Gaussian filter (σ = 20). If the artery lumen is parallel to
the z-axis, the centerline will be identified and no further steps will be necessary.
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3. Compute tangent vectors τi,k to ci,k. Tangent vectors τi,k to the centerline ci,k are computed using a finite difference
second-order method.
4. Compute planes pii,k orthogonal to the tangent vectors τi,k. In this step, the planes pii,k orthogonal to the tangent
vectors τi,k are determined.
5. Compute slice extraction on pii,k with the artery lumen to evaluate the ci+1,k. The slices are extracted using a
linear interpolation. Here, a relaxation method is introduced to stabilize convergence for centerline identification. The
extracted slices allow for calculating the centerline points c j,k. In the next iteration, the centerline ci+1,k is determined
by ci+1,k = (1−β )c j,k+βci,k, setting the relaxation parameter beta to β = 0.5 for the Datasets #1, #2, and #3A and
β = 0.9 for the Dataset #3B and finally smoothed using the Gaussian filter. Thus, the residual ρ of the centerline ci−1,k
and ci,k is computed, being ρ = ∑
Nk
k=1 d(ci−1,k,ci,k)/Nk and i the number of iterations. If ρ > µ , the algorithm returns
to step 3, with the threshold µ = 0.3 voxel length being well below one voxel length; otherwise, the iteration loop is
terminated and the centerline c f inal,k, the tangent vectors τ f inal,k, and the planes pi f inal,k are found.
6. Cross-sectional areas along the artery lumen position. In this step, slices orthogonal to the tangent vectors τ f inal,k are
extracted from the volumetric data of the artery lumen and their cross-sectional areas computed.
Histology
Histological sections were prepared from the decalcified artery according to a standard protocol6. Briefly, three slices, each
about 2 µm thin, were cut along the artery. The slices were colored with three selected stains, namely hematoxylin and eosin
(H&E), Miller or Masson’s Trichrome, and mounted on glass slides. Images of the histological slides were taken using the
Panoramic MIDI scanner (3DHistech, Sysmex Suisse) with a pixel resolution of 0.24 µm.
Data registration
One height step selected from Dataset #1 was successfully registered to the corresponding height step of Dataset #2, using
an affine registration algorithm27. Three-dimensional registration was carried out using the classical maximization of mutual
information28, 29 (see CT-slices in Fig. 1a). The same procedure was applied to the Datasets #3A and #3B (see CT-slices in
Fig. 1b). To match the histology and tomography data (#3A), slice-to-volume registration19 was performed. To facilitate
the comparison with the tomography data, and prior to registration, the histology images were binned by a factor of 20 and
converted to grayscale.
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Imaging parameters
Label Specimenpreparation Modality X-ray source
E
[keV]
Detector type
(pixel used)
l
[µm] N
t
[s]
T
[h]
h(n)
[mm]
#1
Formalin
fixation XGI phase P07, DESY 45
CMOS
(5120×3840) 1.3 1800 0.2
∗ 21.3 21.9 (10)
#2
Paraffin
embedding XGI phase P07, DESY 45
CMOS
(5120×3840) 1.3 1200 0.2
∗ 15.6 13.9 (6)
#3A Decalcified absorption P05, DESY 10
CCD
(3056×3056) 2.4 1200 1.5
# 9.3 10.3 (4)
#3B Decalcified absorption conventional ≤ 15 CMOS
(1944×1536) 5.2 1200 2.3
# 6.9 16.6 (4)
Table 1. Specimen used and imaging parameters E: photon energy; l: effective pixel length; N: number of projections; t∗:
exposure time per phase step image; t#: exposure time per projection image; T : total artery scan time; h: total artery scan
height; n: number of height steps.
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Figure 1. Selected slices from 3D-3D-registered CT-data before (a) and after decalcification (b) showing clearly the
impact of water replacement. (a) The phase contrast CT-slice from Dataset #1 (left) and the corresponding one from Dataset
#2 (right) were acquired using a double grating interferometer. In the images, the black to yellow color represents the plaque,
which allows for registration, as its size and shape hardly change, whereas the vessel walls given in light gray exhibit massive
shrinkage. (b) The absorption CT-slice from Dataset #3A (right) and the corresponding one from Dataset #3B (left) elucidate
that lumen segmentation is a challenge and automatic procedures will probably fail due to vessel wall damage.
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Figure 2. Rendering of the computed centerlines and the related residual ρ . (a) Results for the centerlines obtained
from the first to the fourth as well as the eighth iterations, derived from Dataset #1, are shown in colors ranging from dark blue
to light green. (b) Part of the centerlines from (a) and the corresponding lumen are viewed from two perspectives. (c) The
color-coded residuals are plotted vs. the iteration steps. Iterations 5 to 7 are not represented in (a), and the orthogonal axes of
the scale bar correspond to a length of 1 mm each.
15/22
22 2 Results
Position along the artery lumen [mm]
Position along the artery lumen [mm]
C
ro
s
s
 s
e
c
ti
o
n
a
l 
a
re
a
 [
m
m
2
]
S
h
ri
n
k
a
g
e
 [
%
]
0 5 10 15
0 5 10 15
0
20
40
60
80
0
1
2
3
4
5
6
#1 - #2
#1
#1
#2
Figure 3. Cross-sectional area obtained from Datasets #1 (black dots) and #2 (red dots) along the segmented artery
lumen, and related shrinkage (brown hollow dots). The reduction of the cross-sectional area in Dataset #1 allowed for
localizing the plaque-related constriction (top panel). Non-uniform shrinkage (bottom panel) as a result of paraffin embedding
prevented any meaningful determination of stenosis. Using the plaque, the two datasets were perfectly aligned. The
gray-shaded box (top panel) indicates the location of the data represented in Fig. 4.
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Figure 4. Cross-sectional area along the artery as derived from Dataset #3A (blue dots) and Dataset #3B (orange
dots). The cross-sectional areas overlap from position 1.2 to 2.6 mm. Damage introduced during the re-embedding procedure
hampered the lumen segmentation of both datasets. Red- and black-dashed boxes indicate regions where the lumen
cross-section was either overestimated (Dataset #3A) or affected by 20-voxel-wide erosion/dilation (Dataset #3B).
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Figure 5. Joint histogram and individual histograms of the registered volumes from Datasets #3A (bottom, left) and
#3B (top, right). The peaks of the histograms were fitted with multi-Gaussian distributions (yellow curve). Whereas the
individual histograms are given by a linear scale, the joint histogram is plotted on a logarithmic scale.
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Figure 6. Joint histogram and individual histograms of the registered volumes from Datasets #3A after applying a
Gaussian filter (bottom, left) and #3B (top, right). Filtering Dataset #3A gave rise to sharper peaks, which overlapped
without filtering (see Fig. 5, bottom left).
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Figure 7. Comparison of histology slices and their CT counterparts from Dataset #3A. The selected micrographs of the
histological sections (left) of the decalcified human coronary artery were stained using H&E, Miller, and Masson’s Trichrome.
Tomography slices (right) matching the histological sections were identified by automatic registration.
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Figure 8. Magnified parts of the slices shown in Fig. 7. The histological slice, stained by Masson’s Trichrome (left),
exhibits anisotropic deformation resulting from the cutting process, as recognizable by comparison with the counterparts from
the Datasets #3A (middle) and #3B (right). After histological sectioning, part of the tissue drastically deforms (dashed black
circle) or is lost (black arrow).
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Figure 9. Effect of the median filter on the lumen area. Hundred tomography slides from Dataset #2 segmented after
applying a median filter with a kernel size of 15 (red dots); two arbitrarily selected CT-slides, with no filter applied, segmented
by three individuals (hollow squares, data presented as mean values, including error bars derived from the standard deviation, n
= 3). Data filtering caused constant lumen enlargement over all the CT-slides, and therefore the lumen cross-section was eroded
by one voxel (blue dots).
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Figure 10. Flow chart describing the implemented iterative procedure. The flow chart shows the main steps employed to
determine the centerline and the cross-sectional area along the artery lumen.
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ABSTRACT   
Cardiovascular diseases are the worldwide number one cause of mortality. The blood flow in diseased human coronary 
arteries differs from the blood flow in the healthy vessels. This fact should be used for designing targeted localized 
delivery of vasodilators with a purely physical drug release trigger. Thus, we have proposed mechano-sensitive 
liposomes as mechano-sensitive containers. One has to tailor the liposome’s properties, so that containers are stable 
under physiological conditions in health, but release their cargo near the constricted vessels at body temperature. In order 
to determine the shear stress threshold for release, both the morphology of the healthy and diseased human arteries and 
the mechanical property of the liposomes have to be known. We have shown that micro computed tomography (µCT) 
techniques allow visualizing the lumen of human coronary arteries and provide the basis for flow simulations to extract 
the wall shear stress of healthy and stenosed regions in human coronary arteries. The behavior of the mechano-sensitive 
liposomes is currently investigated by means of microfluidics and spatially resolved small-angle X-ray scattering. The 
liposomes are injected into micro-channels mimicking in vivo situation. The scattering signal from the liposomes reveals 
information about their size, shape, and wall thickness. 
Keywords: Drug delivery, liposome, micro computed tomography, stenosed human artery, mimicking, microfluidics, 
flow simulation, small-angle X-ray scattering 
 
1. INTRODUCTION  
Heart and blood vessel disease includes numerous problems, many of which are related to atherosclerosis. 
Atherosclerosis develops when the accumulation of white blood cells and the proliferation of intimal-smooth-muscle 
cells lead to a fibro-fatty plaque. Plaques create a thickening of the artery walls. The thickening narrows the vessel 
diameter, making it harder for blood to flow through. If a blood clot forms, it can block the blood flow leading to heart 
attack or stroke [1]. Infarcts are often treated with vasodilator drugs. A systemic administration of these substances has 
the drawback of lowering the patient’s blood pressure, as all vessels including the veins increase in diameter. Therefore, 
a localized release of vasodilator is beneficial. 
At the location of the constriction, the blood flow in diseased human coronary arteries differs from that in healthy 
arteries [2]. Therefore, one may overcome the systemic delivery of vasodilators and use the modified flow as a purely 
physical trigger for drug release. We have recently reported on a shear stress-sensitive liposomal formulation for the 
treatment of myocardial infarction via the release of a vasodilator drug [3]. The liposomes, around 100 nm in diameter, 
consist of phospholipids organized as shown in Figure 1. The novelty of such lentil-shaped liposomes relies on their 
sensitivity to local shear stress present in human arteries. At the constrictions, the blood velocity is significantly 
increased and thus the wall shear stress. The enhanced shear stress should trigger the drug release. To further enhance the 
technology, the morphology of stenosed human coronary arteries has to be determined with the necessary precision and 
the mechanical properties of the mechano-sensitive liposomes have to be investigated and adapted accordingly. 
Micro computed tomography (µCT) allows non-destructively imaging hard and soft tissues. The spatial resolution 
reaches the true micrometer scale [4]. Absorption and phase contrast-based tomography modes are widely used to study 
hard tissues such as tooth crowns [5], and soft tissues such as brain [6] and tumors [7]. The µCT data of human coronary 
arteries [8, 9] allows for a deeper understanding of the morphology in healthy and diseased situations. 
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Recently, the shear-stress sensitive liposomes were tested with respect to complement activation related-
pseudoallergy (CARPA). Surprisingly, no significant complement activation was found in human sera and pig plasma 
[10]. Accordingly, animal experiments with pigs have shown much less reactions than liposomal formulations approved 
by the FDA [10]. 
To investigate the morphology of self-assembled phospholipid liposomes small-angle X-ray scattering (SAXS) is a 
powerful and widely used method. SAXS measurements are usually performed in wax-sealed glass capillaries [11, 12]. 
Information on liposome’s parameters in terms of shape, size, and bilayer thickness can be extracted. Measurements in 
glass capillaries, however, do not allow for the detection of structural changes of the liposomes, while temporal and 
spatial conditions change. Microfluidics combined with SAXS is a valuable tool to investigate biological matter [13, 14]. 
It can be used to characterize how the liposomes react to changes in shear stress by tuning the flow conditions (shear 
rate) within the microfluidic device in order to mimic clinically relevant situations. The microfluidic system consists of a 
flexible, reproducible X-ray compatible device with a well-defined geometry to mimic healthy and diseased blood 
vessels. Knowing the artery morphology and the magnitude of the wall shear stress in normal and stenosed blood vessels, 
the mechanical properties of the liposomes can be investigated by adjusting the flow condition in the microfluidic device, 
accordingly. 
 
Figure 1. Schematic drawing of shear-stress sensitive phospholipid Pad-PC-Pad with an inner cavity shown in yellow, 
available for the vasodilator. At enhanced wall shear stress, as present in the diseased sections of arteries, the drug should be 
released. The chemical structure of the liposome is also given. 
2. MATERIALS AND METHODS 
2.1 Microfluidic device preparation 
X-ray compatible microfluidic devices have been produced as previously described [15-17]. The main steps for 
preparing a microfluidic device are illustrated in Figure 2. Photolithography of SU-8 negative resist on silicon wafers 
was used to fabricate masters for the device fabrication. A layer of resist, either 50 or 100 µm thick, was exposed to UV-
light through a photo mask containing the microfluidic design and was afterwards developed. PDMS and cross-linker 
were mixed at a ratio of 10:1 to form flexible replica stamps. The liquid PDMS mixture was poured on the 
photolithographic master and cured overnight at a temperature of 80 °C. Afterwards, the PDMS stamp was peeled off 
from the master. Norland Optical Adhesive 81 (NOA 81) was coated on a polyimide film 25 µm thick and the PDMS 
stamp was placed on the NOA 81 coated polyimide film in order to imprint the microfluidic structure into the NOA 81 
coat. After exposure under UV light, λ = 366 nm, to crosslink NOA 81, the flexible PDMS stamp was peeled off. By 
using a puncher 0.75 mm in diameter, inlet and outlet holes were obtained. The microfluidic NOA 81/polyimide device 
was sealed with a second polyimide film, cured, and tightly bound for the related measurements. 
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Figure 2. Microfluidic devices are fabricated using soft lithography combined with poly(di-methylsiloxane) (PDMS), UV-
curable adhesive material NOA and polyimide film. The pattern of the microfluidic device consists of a main channel with a 
constriction to reproduce the morphology of a constricted blood vessel. 
2.2 Micro computed tomography 
Micro computed tomography measurements were performed on a nanotom® m (GE Sensing & Inspection Technology, 
GmbH, Wunstorf, Germany) with tungsten target at an acceleration voltage of 40 kV and beam current of 450 µA. Two 
devices, presenting 50 µm and 100 µm constrictions, respectively, were scanned. The devices were mounted on a high 
precision manipulator and continuously rotated by 360° through the X-ray beam, cf. Figure 3, within a period of eight 
minutes. During specimen rotation, 959 projections with an exposure time of 0.5 s each were acquired. Data 
reconstruction was performed with the supplier’s software datos|x 2.2. 
 
Figure 3. Schematic of µCT setup: the specimen is placed on a rotation axis between the X-ray source and the detector. A 
photograph of the laboratory µCT used for the present study, i.e. nanotom® m (GE Sensing & Inspection Technology, 
GmbH, Wunstorf, Germany) is represented. 
2.3 Flow simulations 
The simulations were carried out using COMSOL Multiphysics 4.3a (COMSOL, Palo Alto, CA, USA) by numerically 
solving partial differential equations using the finite element method (FEM) [18]. The used mesh of the microfluidic 
constriction consisted of 624’355 elements. The NAVIER-STOKES equation was solved for an incompressible fluid in 
laminar flow with the constriction geometry and no-slip boundary conditions at the walls. For the simulations a volume 
flow rate of Qin = 1 µL/s, density ρ = 1000 kg/m3, and dynamic viscosity η = 8.9.10-4 Pa.s were assumed. 
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2.4 Small-angle X-ray scattering 
Laboratory-based X-ray source: In-house SAXS measurements were carried out using a Bruker Nanostar setup with a 
microfocus X-ray source (Cu-Kα-radiation, λ = 1.54 Å). The beam was collimated to reach a diameter of 200 µm. The 
signal was recorded using a 2D HiStar detector (Bruker AXS, Madison, WI, USA). The aqueous suspension containing 
the phospholipid liposomes was measured in a glass capillary under vacuum conditions. The glass capillary was 1.5 mm 
in diameter with a wall thickness of 10 µm. 
Synchrotron radiation-based X-ray source: SAXS data were acquired at the cSAXS beamline of the Swiss Light 
Source storage ring (PSI, Villigen Switzerland) [19] using a photon energy of 12.4 keV. The X-ray beam was focused to 
40 µm × 40 µm spot size at the specimen location, 2.2 m upstream from the PILATUS 2M detector [20]. Measurements 
were performed on microfluidic devices scanning 150 lines across the channel. The micro-channel was filled with a 
20 mg/ml DPPC/DSPE-PEG2000 (95:5 mol %) solution in PBS. Flow rate was adjusted to 0.083 µL/s by using a syringe 
pump system (Nemesys, Cetoni GmbH, Korbussen, Germany). The micro-channel was connected to the pump using 
Teflon (PTFE) tubing. 
3. RESULTS AND DISCUSSION 
3.1 Mimicking the geometry in human coronary artery by using microfluidic devices  
High-resolution hard X-ray computed tomography in absorption mode has been used to characterize human coronary 
arteries [2, 8]. To better understand how the mechano-sensitive liposomes behave, when the diameter of a blood vessel 
changes, one may take advantage of microfluidic channels with suitable geometry. They are invaluable tools to mimic 
the in vivo situation. In Figure 4, the µCT-slice shows the cross section of a human diseased coronary artery (left image). 
One recognizes the vessel wall in light grey, the surrounding tissues represented by white and dark grey spots, and the 
plaque in white that obstructs the blood flow along the artery. We have also used µCT to visualize the cross sections of 
the microfluidic channels. The central and right parts of Figure 5 show selected cross sections of the micro-channels with 
two prepared geometries. The 200 µm-wide micro-channels decrease to 50 and 100 µm, respectively. These geometries 
with 75 % or 50 % narrowing are suitable to test liposome properties changing flow rate and temperature. 
 
Figure 4. Left: A cross section through the µCT data of a human coronary artery with a cholesterol plaque (white) 
obstructing one of the vessels. The vessel walls (light grey) and the surrounding tissues (white and dark grey spots) are 
visible. Central column: View of two 200 µm-wide micro-channels with 50 µm- (top) and 100 µm-wide (bottom) 
constrictions. Right: Cross sections through same micro-channels at non-constricted and constricted locations. 
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3.2 Microfluidic flow simulation: Velocity and shear rate profiles 
Flow simulations predict the profile of the shear stress in the microfluidic channel. Figure 5 shows the velocity and the 
shear rate profiles found by simulation and analytical solution for a microfluidic channel designed to mimic the healthy 
and constricted areas of a blood vessel. The channel width changes from 200 to 50 µm over a distance of 50 µm. The 
parabolic trend of the velocity field is present along the entire micro-channel. The velocity exhibits the highest value in 
the center of the device and decreases toward the walls. On the contrary, the shear rate is zero in the center of the channel 
and increase up to 7.7 104 s-1 at the walls according to the analytic solution, for a flow rate of 1 µL/s. The average shear 
rate yields 4.0 104 s-1. The trend can be better visualized from the cross section of the micro-channel (see zoom), both in 
the wide and in the constricted areas of the micro-channel. 
The shear stress in blood vessels is the fluid viscosity times the shear rate [21]. The liposome properties have to be 
tested in a shear stress range compatible with that found in constricted arteries. From flow simulation on human coronary 
arteries and µCT data, the shear stress in normal arteries was found to be below 5 Pa, whereas in the constricted areas it 
was above 15 Pa [2]. By adjusting the flow rate through the microfluidic device by means of the syringe pump, the 
desired shear stress in the channel can be realized. To mimic the in vivo wall shear stress conditions by using the 
microfluidic device with a constriction of 50 µm × 50 µm, the flow rate of the aqueous solution can be set to 0.021 µL/s, 
which corresponds to a shear stress of 1 Pa (healthy case). Higher flow rates, such as 0.33 µL/s, are used to get shear 
stresses of around 16 Pa (diseased case). 
 
Figure 5. Flow simulations showing the velocity (a) and shear rate (b) profiles for a straight polyimide-based micro-channel 
200 µm wide with a constriction 50 µm wide. The height is fixed to 50 µm. The flow rate is set to 1 µL/s. The red-colored 
arrow shows the flow direction. The zoom of cross sectional slide shows the analytical solution as insert. 
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3.3 SAXS measurements of liposomes in glass capillaries and microfluidic devices 
Preliminary measurements to test the accessibility of SAXS signal of liposomes were performed both on glass capillaries 
in a lab setup and in microfluidic devices at a synchrotron radiation source (SLS, PSI, Villigen, Switzerland). Figure 6 
shows, on the left side, a schematic experimental setup of the SAXS experiments. The SAXS-signal is collected on a 2D 
detector around a direct microfocus X-ray beam, which is absorbed in the beam stop. The SAXS signal is azimuthally 
integrated to obtain the q-plots, i.e. the intensity versus scattering angle. Results shown here were obtained from DPPC 
liposomes prepared as previously described [3]. The momentum transfer q (reciprocal space) is inversely proportional to 
the related real-space distances d (d = 2π/q). In Figure 6, right side, the q-plots from lab source (blue-colored triangles) 
measured in a glass capillary and synchrotron radiation source (red-colored dots) collected in the microfluidic device are 
shown. The scattering signals show similar behavior and are characterized by a shoulder for q = 0.01 Å-1 (d = 62.8 nm) 
indicating the average size of the liposomes; a bump is visible for higher q values, indicating the thickness of the 
phospholipid bilayer. It was found to be around q = 0.1 Å-1, which corresponds to d = 6.3 nm. This value for DPPC in the 
L-alpha phase agrees with the value of 6.5 nm reported in literature [22, 23]. Similarity of the curves underlines the 
feasibility of phospholipid liposomes investigation in microfluidic devices. The obtained signal is comparable to that 
from measurements in glass capillaries, considered as standard, and no apparent interference from the devices could be 
found. 
 
Figure 6. On the left, a scheme of the SAXS setup; on the right the q-plot showing the SAXS signal of liposomes measured 
both by using an in-house setup (blue-colored triangles) and at synchrotron radiation facility (red-colored dots). In house 
measurements were carried out in glass capillary, whereas the microfluidic channels were tested at the synchrotron radiation 
source. 
4. SUMMARY AND CONCLUSION 
The task to characterize the release of vasodilator drugs from mechano-sensitive containers of nanometer size is 
challenging. Since the phenomenon could not be reliably assessed within the patient, suitable in vitro set-ups have to be 
realized. Microfluidic systems belong to the key devices that allow for the detailed understanding of the release 
mechanisms and a related optimization of the liposomal formulations. Such devices have to mimic both healthy and 
diseased situations. Here, flow simulations of the designs are helpful, but also need to be complemented by experiments 
as a counterpart to the patient’s blood vessels. To this end, high-resolution three-dimensional imaging of both devices 
and human arteries has to be performed in detail. 
In a next step, the microfluidic systems are applied to study the behavior of liposomes along the simulated blood 
stream by means of spatially resolved X-ray scattering, which gives access to potential structural changes due to shear 
stress adaptations. 
Although shear-sensitive liposomes are already identified, extensive scientific work has to be invested before the 
first patient might benefit from such a physically triggered mechanism. Thus, further experiments will be performed 
using techniques as rheology combined with both light scattering and small-angle neutron scattering and microfluidics 
combined with fluorescence microscopy. 
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Currently, the mechanical properties including the stiffness as function of temperature, polymer length, and nano-
container size are locally studied using atomic force microscopy. 
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Abstract
Atherosclerosis gives rise to blood vessels occlusion associated with blood ﬂow al-
teration and substantial increase of average wall shear stress. This modiﬁcation was
proved acting as a purely physical trigger for targeted vasodilator release from 1,3-
diaminophospholipid (Pad-PC-Pad) liposomes. The ﬂow-induced structural changes of
the faceted liposomes, however, are completely fameless. Therefore, spatially resolved
small-angle X-ray scattering was combined with microﬂuidics. The microﬂuidic device,
designed to mimic a stenotic blood vessel, consisted of a horizontal channel 1 mm wide
with a constriction 125µm in diameter. Here, the changes of the average bilayer thick-
ness and the mean size of the mechano-responsive liposomes have been detected locally.
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Overall shape and bilayer thickness do change already near the constriction inlet, but
the alteration is dominant near the outlet. At a ﬂow rate of 0.2 µL/s, the liposome's
bilayer thickness increased by 30% compared to the thickness well before the constric-
tion and under static condition. The detected bilayer thickness increase of the faceted
liposomes is in line with the mechanically induced loss of interdigitation between the
phospholipid amide chains. These results imply that rather the gradient in the wall
shear stress than the amplitude provokes structural changes of Pad-PC-Pad liposomes
and the related drug release at stenosis.
1 Introduction
The local dysfunction of arteries can expose the patient to life-threatening situations, includ-
ing myocardial infarction. Under these circumstances, the heart is insuﬃciently supplied with
oxygen via coronary arteries. Here, the delivery of vasodilatory drugs is necessary and ap-
propriate, although adverse eﬀects have been reported.1 Stenosed arteries have a drastically
altered morphology with a cross section reduction, which causes a substantial increase of
the blood ﬂow velocity and, as a consequence, gives rise to an increase of the average wall
shear stress by at least one order of magnitude.2 It has been proposed that this increased
shear stress could be used as a purely physical trigger for targeted vasodilator delivery.3,4
Nanometer-sized liposomes are powerful containers to entrap, transport, and deliver a wide
variety of drugs in the human body.5,6 The artiﬁcial 1,3-diaminophospholipid, Pad-PC-Pad,7
self-assembles in aqueous solution and can form faceted liposomes.3,8 These liposomes are
stable at rest and release their cargo at elevated shear stresses.3 The mechanism behind,
however, is hardly understood and was previously related to an attenuation of the defects in
the contact lines between the facets of a vesicle.9
Understanding how Pad-PC-Pad liposomes behave under dynamic condition might sup-
port them as powerful drug delivery system. In fact recent studies report that the adverse
eﬀects observed for bare and nitroglycerin-loaded Pad-PC-Pad liposomes in vitro and in vivo
2
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are comparable or even lower than for established liposomal formulations.10,11
In order to quantitatively assess the structure of liposomes, many methods have been em-
ployed including nuclear magnetic resonance (NMR),12 dynamic light scattering (DLS),13
cryogenic transmission electron microscopy (Cryo-TEM),14 as well as small-angle X-ray
and neutron scattering (SAXS and SANS).15,16 SAXS is of particular interest, because this
method gives access to numerous characteristic quantities of the liposomes in terms of shape,
size, lamellarity, and bilayer thickness. Garcia et al. have shown, for example, that SAXS
allows not only for the determination of size, but also for the structural dependence on the
solvent used and the osmotic shrinkage of a complex liposomal drug.15 SAXS, however, does
not only enable to perform static measurements, but the combination with microﬂuidics per-
mits dynamic studies,17 i.e. studies of the mechano-responsive properties of non-spherical
liposomes. Spatially resolved SAXS using synchrotron radiation18 has been applied to vi-
sualize human tissues in two dimensions19,20 and more recently even in three dimensions.21
It has been also used to map soft matter within a ﬂow ﬁeld.22 The payoﬀ of combining
microﬂuidics and SAXS can been seen for diverse examples. One can observe the mixing
of ﬂuids,23,24 the in situ, real-time changes of the structural properties of proteins,23,25 of
DNA,26 of surfactant solutions,27 of polymers,28 of liquid crystals,29 of worm-like micelles,22
and of nanocapsules.30 Poulos et al. have reported that under shear, the lamellar phases
of highly concentrated complex surfactant solutions depend strongly on the ﬂuid direction.
Multi-lamellar phases, subjected to the identical ﬂow ﬁelds, were insensitive to contraction-
expansion ﬂows.27 The study, however, is limited to the ﬂow ﬁeld on the lamellar periodicity
and does not include overall shape alterations.
Herein, we examine how Pad-PC-Pad liposomes in low-concentration suspension responds
to shear-stress changes by tuning the ﬂow conditions in a microﬂuidic device. The design
of the device mimics constricted blood vessels. In this manner, the alterations of the shear
stress in wide (healthy) and constricted (diseased) segments of the device (artery) can be
simulated. It should be noted that three q-ranges were of speciﬁc interest and includes the
3
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size of the liposomes and the size of the bilayer thickness. The q-range of the SAXS pattern
covers two orders of magnitude. The two-dimensional data represent the modiﬁcations in
the ﬂow ﬁeld as a function of the ﬂow rate.
2 Materials and Methods
2.1 Liposomes preparation
Two phospholipids, the commercially available natural 1,2-dipalmitoyl-sn-glycero-3-phospha-
tidylcholine (DPPC) with 5% molar DSPE-PEG2000 (Lipoid, Zug, Switzerland) and the
1,3-palmitoyl-amido-1,3-deoxy-sn-glycero-2-phosphatidylcholine (Pad-PC-Pad) synthesized
according to the recently reported protocol,7 were used to prepare liposomes. Brieﬂy, the
liposomes were formulated via the standard thin-ﬁlm method31,32 and hydrated with ultra-
pure water. Each suspension obtained has a lipid content of 20 mg/mL, which corresponds to
the highest concentration achievable using Pad-PC-Pad. The suspensions were freeze-thawed
in a twelve-step series of liquid nitrogen cooling and water bath heating (60 ◦C). To obtain
liposomes with a diameter of about 100 nm with a narrow size distribution, multiple barrel
extrusions using Liposofast LF-50 (Avestin Inc., Canada) through track-edged polycarbonate
ﬁlter membranes (Whatman Nucleopore, Sigma-Aldrich, Buchs, Switzerland) were applied.
The pore sizes were reduced from 400 nm (ﬁve times) via 200 nm (ﬁve times) to 100 nm (15
times).
2.2 Liposomes characterization
The lipid concentration of the two formulations was determined using the phosphate test.33
Size and size distribution of the liposomes were quantiﬁed by means of dynamic light scat-
tering (DLS) using a Delsa Nano C (Beckman Coulter, USA). DLS measurements were
performed at a temperature of 25 ◦C, using two laser diodes working at a wavelength of
658 nm. The scattering angle was set to 165 degrees. Cryo-TEM images of Pad-PC-Pad
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liposomal suspension were taken by mounting the liposomal suspension on glow-discharged
holey carbon grids, quickly frozen by a Cryoplunge CP3 system (Gatan, USA), and trans-
ferred to a JEM2200FS transmission electron microscope (JEOL, Japan) using a Gatan626
cryo-holder. Cryo-TEM micrographs were recorded at an acceleration voltage of 200 kV at
a magniﬁcation of 20,000, 4-8 µm under-focus, and a dose of 10 electrons/Å
2
, using a F416
CMOS detector (TVIPS, Germany).
2.3 Microﬂuidic device fabrication
X-ray compatible microﬂuidic devices were prepared as reported previously.22 Brieﬂy, pho-
tolithography of SU-8 negative resist (Nano SU-8 100, MicroChem Corp., MA, USA) on Si
wafers was used to fabricate the masters. A layer of 250µm thick photoresist was exposed
to UV light through a photo mask with the microﬂuidic design and was afterwards devel-
oped. The microﬂuidic device design consisted of a horizontal channel of 1000µm width
with a constriction in the middle 2000µm long. Two designs were realized, with constriction
widths of 125µm and 250µm. Polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning
Corp., Midland, USA) and crosslinker were mixed at a ratio of 10:1 to form ﬂexible replica
stamps. The liquid PDMS mixture was poured on the photolithographic master and cured
overnight at a temperature of 80 ◦C. Afterwards, the PDMS stamp was peeled oﬀ from the
master. Norland Optical Adhesive 81 (Norland Products Inc., Cranbury, USA) was poured
on a polyimide ﬁlm of a thickness of 25µm (Goodfellow Corp., Cambridge, UK). PDMS
stamp was placed on the NOA 81 coated polyimide ﬁlm in order to imprint the microﬂuidic
structure into the NOA 81 coat. After 1 min exposure to UV light, λ= 366 nm, to crosslink
NOA 81, the ﬂexible PDMS stamp was peeled oﬀ. By using a puncher 0.75 mm in diameter,
inlet and outlet holes were obtained. The microﬂuidic NOA 81/polyimide ﬁlm was then
sealed with a second polyimide ﬁlm with a thickness of 25µm.
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2.4 SAXS measurements
The spatially resolved SAXS measurements were performed at the cSAXS beamline at the
Swiss Light Source (PSI, Villigen, Switzerland). The X-ray beam was focused to 25µm ×
50µm (vertical × horizontal) spot size at the specimen location, the photon energy was
set to 11.2 keV (l =1.1Å), and the sample-detector distance to 7.102 m, determined by the
ﬁrst scattering order of a silver behenate specimen. The scattering signal was recorded us-
ing the Pilatus 2M detector34 (pixel size: 172µm × 172µm). Dynamic spatially resolved
SAXS measurements of the liposomal suspensions were performed using microﬂuidic devices
mounted on an aluminum/polyetheretherketone/aluminum sample holder. Two-dimensional
(2D) scans were realized line-by-line by continuously moving the device in horizontal direc-
tion, while the detector recorded the data in burst mode. 48 (v) × 96 (h) points at step
size 25µm (v) × 50µm (h) were acquired in a pre-selected region of the microﬂuidic device
with an exposure time of 1.5 s per point. The data were processed using the Matlab package
available from the beamline (https://www.psi.ch/sls/csaxs/software). During the experi-
ment, the ﬂow rates were adjusted using a syringe pump system (Nemesys, Cetoni GmbH,
Korbussen, Germany) connected to the microchannel using polytetraﬂuoroethylene (PTFE)
tubing. For the point-wise background correction, the scattering signal of ultra-pure water in
the microﬂuidic device for all the measured ﬂow rates was recorded before the acquisition of
the SAXS signal of the liposomal suspensions. For the microﬂuidic device with a rectangular
channel cross-section, the wall shear rates γ were calculated from the volumetric ﬂow rates
v using the following equation:30
γ = 6v/h2w (1)
with γ the shear rate [s−1], v the volumetric ﬂow rate [µL/s], and w and h the width and
height [µm] of the channel, respectively.
In addition, static SAXS measurements of the two liposomal suspensions and the ultra-
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pure water were carried out in boron silicate glass capillaries (Hilgenberg, Malsfeld, Germany)
having an outer diameter of 1.5 mm and wall thickness of 0.01 mm using the parameters given
above.
3 Results and Discussion
3.1 Liposomes characterization
The ﬁnal concentration of Pad-PC-Pad liposomes was (19.6 ± 1.3) mg/mL, whereas that of
DPPC/DSPE-PEG was (20.2 ± 6.5) mg/mL.
The DLS results showed a mean diameter of (131.6 ± 0.9) nm for Pad-PC-Pad and
a polydispersity index (PDI) of (0.103 ± 0.009), whereas for DPPC/DSPE-PEG a mean
diameter of (101.3 ± 0.5) nm and PDI of (0.256 ± 0.005) was found.
The Cryo-TEM micrograph in Figure 1 shows the morphology of Pad-PC-Pad, charac-
terized by faceted and lentil-like shape.3,9 The overall diameter appears to be in the range
100 nm to 200 nm, in agreement with DLS. The presence of round liposomes can be linked
to the projective nature of cryo-TEM, as lenticular shapes seen top-on or slightly tilted will
appear round. Nevertheless, the presence of spherical liposomes cannot be excluded.
3.2 SAXS measurement under static condition
The investigated q-range between 0.02 nm−1 and 1.65 nm−1 corresponds to real-space dis-
tances d between 314 and 3 nm and, therefore, covers almost the entire nanometer range
relevant for the characterization of the liposomes. The diagrams in Figure 2 show the radi-
ally integrated scattering signal of DPPC-DSPE/PEG (top panel) and Pad-PC-Pad (bottom
panel) liposomes acquired in suitable glass capillaries.
For DPPC/DSPE-PEG, the intensity peak at around 1.1 nm−1, corresponding to 5.7 nm
in real space, relates to the bilayer thickness.
7
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200 nm
Figure 1: Cryo-TEM micrograph of Pad-PC-Pad showing faceted liposomes with a size between
100 and 200 nm. The liposomes exhibit a wide variety of shapes.
For Pad-PC-Pad, the peak related to bilayer thickness is located at the edge of the
detectable q-range, which additionally incurs into increased noise, and thus cannot be un-
equivocally characterized.
Suitable models are often utilized in the interpretation of the scattering signal of the
system investigated.35 Herein, the scattering curves of DPPC/DSPE-PEG and Pad-PC-Pad
were both ﬁtted using a decoupling approach, which allowed to factorize the total form factor
as product of a cross section term for long dimension and a cross section term for shorter
dimension.36 To ﬁt the form factor related to the overall shape of DPPC/DSPE-PEG, a thin
spherical shell model was used,37 whereas the intensity peak related to the bilayer was ﬁtted
using a function for a bilayer with a Gaussian electron density proﬁle.38,39 The model utilized
to ﬁt the bilayer provided the bilayer thickness as the distance head-to-head dhh between the
two phospholipid heads and the standard deviation over the phoshpolipid heads.
To account for the polydispersity, the radii R and the dhh were assumed to be normally
distributed with means R = 44.6 nm and dhh = 2.4 nm.
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The DPPC/DSPE-PEG liposomes mean diameter of 89.2 nm is smaller than the mean
value obtained from the DLS (101.3 nm). It has been reported that DLS provides values
up to 20% higher compared to SAXS, as in SAXS solvent contrast variation does not allow
to detect the hydrodynamic size of PEG bound to the liposomes surface.15 As displayed in
Figure 2 the drop in intensity of the scattering curve of DPPC/DSPE-PEG at the lowest
q-values is attributed to inter-particle interference.40 The addition of PEG was reported
to prevent liposomes aggregation,41 i.e. providing for a repulsive interaction between the
particles. In the model utilized, PEG contribution was not included.
The distance head-to-head dhh = 2.4 nm found for DPPC/DSPE-PEG is in line with the
bilayer thickness value of 5.6 nm reported in Ref. 42, if one includes the calculated standard
deviations 2σ = 3.0 nm over the two phospholipid heads.
To ﬁt the form factor related to the overall shape of Pad-PC-Pad a thin ellipsoidal
shell model was used.37 An eccentricity  of 0.43 was found, in agreement with the value
reported in Ref. 11. As for DPPC/DSPE-PEG, the intensity peak related to the phospholipid
head-to-head distance dhh was ﬁtted using a function for a bilayer with a Gaussian electron
density proﬁle38,39 and a normal distribution over dhh. The results showed a mean value of
dhh = 3.3 nm and standard deviation of 2σ = 1.4 nm over the two phospholipid heads.
At low q-values of Pad-PC-Pad scattering curve, the Guinier approximation43 was used
to determine the radius of gyration (Rg) and found Rg = 60.3 nm with standard deviation
σRg = 0.4 nm (see Table 2), in line with the averaged diameter value obtained from the DLS
(131.6 nm).
3.3 SAXS measurements of Pad-PC-Pad under dynamic condition
The measurement in glass capillaries provided the ﬁngerprint of Pad-PC-Pad liposome struc-
ture in static condition. In order to investigate the behavior of Pad-PC-Pad liposomes under
an external perturbation, such as a shear stress gradient, 2D raster SAXS scans of Pad-
PC-Pad liposomes under ﬂow conditions, produced in a microﬂuidic device, were recorded.
9
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Figure 2: Integrated scattering signals of DPPC/DSPE-PEG (black dots, top diagram) and Pad-
PC-Pad (black squares, bottom diagram) under static condition. The DPPC/DSPE-PEG signal
was ﬁtted with a thin spherical shell model and a bilayer Gauss electron density proﬁle model
(grey line, top panel) with head-to-head distance dhh = 2.4 nm and 2σ = 3.0 nm over the two
phospholipid heads. Pad-PC-Pad scattering signal was ﬁtted with a thin ellipsoidal shell model and
a bilayer Gauss electron density proﬁle model (grey line, bottom panel) with eccentricity  of 0.43,
head-to-head distance of dhh = 3.3 nm and 2σ= 1.4 nm over the two phospholipid heads.
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Three ﬂow velocities v were tested: v = 0.002 , 0.02 , and 0.2 µL/s. The corresponding shear
rates were determined using Eq. 1. From the lowest to the highest ﬂow rate, the shear rates
in the constriction (h = 250µm, w = 125µm) were γ = 1.54, 15.4, and 154.0 s−1, whereas in
the wide region (h = 250µm, w = 1000µm) they corresponded to γ = 0.2 s−1, 2.0 s−1, and
20.0 s−1.
2D maps of the mean scattering intensity in the range ∆q = 0.096 to 0.102 nm−1 corre-
sponding to a real space range ∆d = 65.4 to 61.6 nm between the overall size and the size of
the phospholipid head-to-head distance are shown in Figure 3.
The non symmetric intensity distribution observed in the 2D maps is indicative of the
complex behavior of the liposomes under varying ﬂow conditions, and it is apparent that
the ﬂow rate, and as a consequence, the shear stress, aﬀects the liposomes, giving rise to
variations in scattering signal depending on the location within the device. At the lowest
ﬂow rate, slightly increased intensity on the inlet side was observed.
At the intermediate ﬂow rate, the constriction signiﬁcantly changed the ﬂow ﬁeld, which
accelerated approaching the constriction, diverged in a plume-like shape immediately after
the constriction, and ﬁnally decelerated far from the constriction. Surprisingly, within the
constriction and for the whole length of it, the scattering signal decreased with respect to
its entrance.
For the highest ﬂow rate, a similar behavior was observed, with the diﬀerence that the
intensity distribution at the inlet was inverted, i.e. stronger along the device walls. This
stronger intensity at the device walls is indicative of a stagnation-zone, which was already
incipient at the intermediate ﬂow rate. Immediately after the constriction, a high-intensity
plume akin to that at the intermediate ﬂow rate was observed.
The local modiﬁcations of the averaged scattering intensity distribution observed in the
2D scanning SAXS maps of Figure 3 supported the selection of seven regions of the mi-
croﬂuidic device, as shown in the sketch of Figure 4. Three regions were selected before the
constriction: one far (#1), one approaching (#2), and one very close (A); symmetrically, on
11
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Flow
v = 0.2 μL/s
v = 0.02 μL/s
v = 0.002 μL/s
log10 (counts/pixel)
-1 1
1 mm
Figure 3: 2D maps of the average scattered intensity at three ﬂow rates v in the q-range
from 0.096 to 0.102 nm−1. At the ﬂow rate v = 0.002 µL/s the intensity appears rather
homogeneous on both sides of the constriction, albeit slightly higher intensity is registered
on the inlet side. At higher ﬂow rates (v = 0.02 ,0.2 µL/s), a signal of increased intensity with
a distinct plume-like shape is visible immediately at the constriction exit, whereas at the
constriction entrance the signal reveals high intensity at intermediate ﬂow rate and reduced
intensity with stagnation zones at the device walls at the highest ﬂow rate.
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the outlet side, three areas were chosen one very close (B), one close (#4), and one far from
the constriction (#5). Region #3 was selected in the constriction avoiding the edges of the
device. For each region, the radially integrated scattering intensity I as a function of the
scattering vector q at each ﬂow rate v is shown.
On the inlet side (regions #1 and #2) no signiﬁcant change at low and medium q can be
observed as a function of v.
The oscillations of I(q) observed at medium q overlap, indicating similar shape and size
distributions of the liposomes. In contrast, the head-to-head distance dhh slightly decreased
with increasing ﬂow, indicated by the shift of the position of the minimum to higher q (see
Table 1).
In region A at the lowest ﬂow rate, the scattering signal was comparable to the one
observed in regions #1 and #2 at all q-ranges. At the intermediate ﬂow rate and at inter-
mediate q the oscillations smeared out. The smearing might indicate a change in the overall
shape of the liposomes.
At v = 0.2 µL/s, the oscillation appeared again more pronounced, similar to the lowest
ﬂow rate, and the position of the minimum shifted to the right, in line with a decrease of
dhh.
Within the constriction (region #3), the scattering curves of the liposomes did not display
any signiﬁcant diﬀerence by varying the ﬂow rate. However, an increase of the Rg values
was observed at the three ﬂow rates (see Table 2) with respect to the static condition and
the regions before the constriction. No signiﬁcant change in the dhh values was detected. It
should, however, be noted that the signal from the constriction is less reliable due to residual
edge scattering from the device walls.
At the constriction exit (region B) the oscillations, still pronounced at the lowest ﬂow
rate, smeared out completely at the intermediate and high ﬂow rate. In fact, the Rg values
reported in Table 2 were comparable to the value found under static condition, but showed
a decrease of about 13% at higher ﬂow rate. Furthermore the minimum shifted to lower q
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values, from 0.50 to 0.45 nm−1 indicating that in this region, the ﬂow ﬁeld caused an increase
of dhh of about 30% compared to the static condition (see Table 1).
The increase of the bilayer thickness of Pad-PC-Pad is in line with a mechanically induced
loss of full interdigitation of phospholipid amide chains, which is usually observed at the
liquid-crystalline phase (above the transition temperature) and, in presence of cholesterol,
at the gel phase (below the transition temperature).44
In region #4, the scattering signal gradually reduced. For the intermediate and high
ﬂow rates the oscillations were smeared, as in region B, whereas for the lowest ﬂow rate the
oscillations were well visible, as in region #2. The position of the minimum did not vary
signiﬁcantly among the three ﬂow rates, indicating no signiﬁcant modiﬁcation on the bilayer
thickness.
In region #5 and at the three ﬂow rates, the oscillations appeared similar as in region
#1. In contrast, the position of the minimum, at the highest ﬂow rate, shifted slightly to
the right, from 0.55 to 0.6 nm−1, compared to the intermediate and lowest ﬂow rate.
Due to the impact of the local ﬂow ﬁeld, alteration of the liposomes morphology in regions
A and B is detected (see Figure 4), both at the high and low q, compared to the other regions
where modiﬁcations, by varying the ﬂow rate, were observed either at low q (e.g., region #5)
or at high q (e.g., region #1,#2).
To highlight the changes of regions A (before constriction) and B (after constriction) at
the three ﬂow rates (see Figure 4), the scattering curves in these two regions were displayed
as normalized diﬀerence of their scattering intensities (see graph in Figure 5).
Herein, three ∆q ranges were selected including the mean overall size of the liposomes
(∆q1 = 0.04 − 0.05 nm−1), the size around the bilayer thickness (∆q3 = 0.83 − 1.12 nm−1)
and a range in between (∆q2 = 0.16 − 0.17 nm−1). 2D maps of the integrated scattered
intensity in each selected ∆q at each ﬂow rate are displayed.
The 2D map at the lowest ﬂow rate and in the range ∆q3 (see Figure 5, bottom right),
showed vertical stripes before and after the constriction, clear sign of the presence of artifacts
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Figure 4: Top left, sketch of the microﬂuidic device showing the seven regions selected. For each
region, the radially integrated scattering signal is plotted for the three ﬂow rates (v = 0.002 µL/s
in blue, v = 0.02 µL/s in green, and v = 0.2 µL/s in orange). Diﬀerences at high q-values are
apparent in the regions before and after constriction, indicating changes in bilayer thickness, and
are pronounced at higher ﬂow rates.
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within the microﬂuidic device. At the three ∆q ranges selected, the 2D maps (see Figure 5)
a trend comparable to the one shown in Figure 3 was observed.
Table 1: Pad-PC-Pad liposomes head-to-head distance dhh under static condition (glass
capillary) and under dynamic condition in the seven regions (see sketch of Figure 4) of the
microﬂuidic device. The data represent the mean values of the normal distribution, including
the associated errors derived from the standard deviation.
dhh [nm]
microﬂuidic device positions
ﬂow rate
[µL/s]
glass
capillary
#1 #2 A #3 B #4 #5
0 3.3±0.8
0.002 3.4±0.7 3.1±0.4 3.4±0.5 3.9±0.7 4.0±0.6 3.9±0.4 3.8±0.3
0.02 3.4±0.7 2.9±0.2 2.9±0.2 3.5±0.6 4.3±0.5 3.6±0.3 3.9±0.4
0.20 3.4±0.9 3.4±0.7 3.2±0.6 3.8±0.8 4.4±0.4 4.0±0.6 4.0±0.7
The response of Pad-PC-Pad liposomes to the ﬂow ﬁeld was compared to the one of
DPPC/DSPE-PEG as reported in Figure 6. Herein, the scattering signals of Pad-PC-Pad
and DPPC/DSPE-PEG were radially integrated in the two areas  blue and red boxes
indicated in the device sketches of Figure 6.
DPPC/DSPE-PEG measurements in dynamic condition were carried out in a microﬂu-
idic device having a constriction width two times wider (wconstriction = 250 µm) than the
one utilized for Pad-Pad-Pad. For a fair comparison, and considering Eq. 1, the same
shear condition at the constriction location was obtained by setting twice the ﬂow rate
for DPPC/DSPE-PEG liposomes than the ﬂow rate to which Pad-PC-Pad liposomes were
subjected.
Whereas signiﬁcant diﬀerences in scattering curves, including the shift of the bilayer peak,
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Figure 5: The graph shows the normalized diﬀerence (IB − IA)/(IB + IA) of the I vs. q curves
in regions A and B (cf. Figure 4) for the three ﬂow rates. Especially for the highest ﬂow rate,
marked diﬀerences are seen in scattering signal, prominently at high q, indicating changes in head-
to-head distance. 2D maps of average scattered intensity are shown for three selected q-ranges
(∆q1 = 0.04 to 0.05 nm
−1, ∆q2 = 0.16 to 0.17 nm−1, and ∆q3 = 0.83 to 1.12 nm−1). As in Figure
3, the establishment of a ﬂow ﬁeld with increasing ﬂow rate can be observed.
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Table 2: Radius of gyration Rg of Pad-PC-Pad liposomes under static condition (glass capil-
lary) and under dynamic condition as a function the microﬂuidic device positions displayed
in the sketch of Figure 4. The data represent the mean values of the normal distribution,
including the associated errors derived from the standard deviation.
Rg [nm]
microﬂuidic device positions
ﬂow rate
[µL/s]
glass
capillary
#1 #2 A #3 B #4 #5
0 60.3±0.4
0.002 59.5±0.2 59.1±0.1 60.3±0.4 63.0±0.5 59.3±0.9 61.1±0.2 61.6±0.2
0.02 60.2±0.2 58.0±0.4 55.1±0.5 64.3±0.6 52.4±0.8 59.1±0.3 61.3±0.1
0.20 61.6±0.4 61.0±0.5 61.4±0.6 64.0±0.8 52.3±0.9 58.0±0.3 60.0±0.4
from the SAXS signals Pad-PC-Pad liposomes before and after the constriction are present,
no changes of DPPC/DSPE-PEG liposomes could be probed, as their scattering signals under
static condition and under dynamic condition (before and after the constriction) overlapped.
The comparison with DPPC/DSPE-PEG liposomes supports our hypothesis that Pad-PC-
Pad liposomes are mechano-responsive, already before the constriction and at the shear rates
here investigated.
4 Conclusions
We have shown that the combination of microﬂuidics and SAXS is valuable technique for
detecting in situ and real time the structure modiﬁcation, at diﬀerent nanometer scales, of
Pad-PC-Pad liposomes which present a broad variety of shape. Modiﬁcation on the Pad-PC-
Pad liposomes, both at high and low q-range, were detected already before the microchannel
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Figure 6: Comparison of the scattering intensity curves for the same maximum shear acting on Pad-
PC-Pad (top) and DPPC/DSPE-PEG (bottom) before (blue-colored dots) and after (red-colored
dots) constriction. A signiﬁcant shift of the bilayer peak of Pad-PC-Pad liposomes is observed
after the constriction with respect to the scattering signal before the constriction and under static
condition (dark-colored dots).
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constriction and at the shear rates here investigated, which are much lower than the ones
found in healthy and stenotic blood vessels.30
We have observed changes in the phospholipid head-to-head distance (high q) of Pad-PC-
Pad liposomes, which decreased while approaching the constriction (Region A) and increased
immediately after the constriction (Region B). The increasing of the head-to-head distance
up to 30% compared to the static condition, suggests that the shear gradient modiﬁes the
membrane defects, which characterize Pad-PC-Pad liposomes membrane, in agreement with
a mechanically induced loss of the interdigitation between the phospholipid chains. Contrary
to DPPC/DSPE-PEG liposomes, Pad-PC-Pad liposomes showed remarkable changes in X-
ray scattering already 1 mm before and after the constriction.
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A B S T R A C T
Liposomes formulated from the 1,3-diamidophospholipid Pad-PC-Pad are shear-responsive and thus promising
nano-containers to speciﬁcally release a vasodilator at stenotic arteries. The recommended preclinical safety
tests for therapeutic liposomes of nanometer size include the in vitro assessment of complement activation and
the evaluation of the associated risk of complement activation-related pseudo-allergy (CARPA) in vivo. For this
reason, we measured complement activation by Pad-PC-Pad formulations in human and porcine sera, along with
the nanopharmaceutical-mediated cardiopulmonary responses in pigs. The evaluated formulations comprised of
Pad-PC-Pad liposomes, with and without polyethylene glycol on the surface of the liposomes, and nitroglycerin
as a model vasodilator. The nitroglycerin incorporation eﬃciency ranged from 25% to 50%. In human sera,
liposome formulations with 20 mg/mL phospholipid gave rise to complement activation, mainly via the alter-
native pathway, as reﬂected by the rises in SC5b-9 and Bb protein complex concentrations. Formulations having
a factor of ten lower phospholipid content did not result in measurable complement activation. The weak
complement activation induced by Pad-PC-Pad liposomal formulations was conﬁrmed by the results obtained by
performing an in vivo study in a porcine model, where hemodynamic parameters were monitored continuously.
Our study suggests that, compared to FDA-approved liposomal drugs, Pad-PC-Pad exhibits less or similar risks of
CARPA.
1. Introduction
Over the last two decades, liposomal formulations, developed as
containers for the targeted and controlled release of drugs, have been
studied in detail [1–3]. Some of these drugs have been approved by the
Food and Drug Administration (FDA) [4]. Controlled drug release over
time in a stenotic artery due to speciﬁc liposome sensitivity on higher
local wall shear stress, can potentially increase the therapeutic index of
an encapsulated vasodilating drug [5]. Simultaneously, when the active
drug, protected by encapsulation, is circulating in the human body, side
eﬀects observed after systemic administration are reduced as often
described for oncological therapeutics [6]. For cardiovascular
treatment agents, hypotension is a characteristic side eﬀect which may
be observed when vasodilating drugs are systemically administered in
case of an acute ischemic event, in order to increase local perfusion
pressure in a suﬀering organ such as the heart, the brain, or the kidneys
[7].
The pathology of atherosclerosis is characterized by the narrowing
and hardening of blood vessels as a result of atherosclerotic plaque
formation [8]. This signiﬁcant narrowing of the arterial blood vessels
alters blood ﬂow and causes changes in the average wall shear stress in
comparison to physiological conditions [9]. It has been reported that an
80%-constricted artery gives rise to a wall shear stress increase of one
order of magnitude [10]. Such an increase of shear stress has been
http://dx.doi.org/10.1016/j.jconrel.2017.08.010
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proposed as a trigger signal for targeted vasodilator delivery [5].
Nanometer-sized, lentil-shaped Pad-PC-Pad liposomes have shown the
unique property of being able to release their cargo under mechanical
stimuli [11]. Targeted drug delivery by these liposomes can be used to
mitigate systemic side eﬀects caused by the intravenous administration
of vasodilators during cardiovascular emergencies. Based on these li-
posomes, we focus on the development of an infusion-based medication
to be given to the patient at any location, for example at the site of a
myocardial infarction. The medication should be active until the patient
reaches the operation theater. As continuous infusion, it should not stay
in the blood stream for prolonged residence time.
Nonetheless, liposomal drugs are often recognized as foreign par-
ticles and hence are attacked by the immune system leading to a bio-
chemical cascade termed complement activation[12]. If there is any
complement activation, it is helpful to understand the mechanism be-
hind the interaction of liposomes with the immune system. In the
serum, there are> 30 complement proteins which usually contribute
as defenders. Some of them can split into fragments when stimulated.
The complement protein cleavage (cf. Fig. 1) can be activated along
three pathways, termed classical, lectin, and alternative [13]. The main
diﬀerences among the three pathways are displayed in Fig. 1. In the
classical pathway, which is mainly mediated by an antigen-antibody
complex (star), the C1 complex (light blue-colored) initiates the acti-
vation of the C3 (light brown-colored) and C5 (orange-colored) proteins
by triggering the proteins C2 (pink-colored) and C4 (green-colored),
thereby giving rise to C3- and C5-convertases. In order to cleave the C5
protein, the immune system can also follow another route, namely the
lectin pathway, which is mediated by the interaction between mannose-
binding lectin (MBL) and the surface of a pathogen, leading to the
cleavage of the C3 and C5 proteins. Cleaved C5 links the proteins C6
(gray-colored), C7 (purple-colored), C8 (dark blue-colored), and the
polymeric C9 (red-colored), thereby producing the complex C5b-9,
known as the Membrane Attack Complex (MAC) or the Terminal Com-
plement Complex (TCC). The MAC induces the formation of a defect in
the cell membrane that damages or destroys the suspected
microorganism, and it can also form via the alternative pathway, due to
interaction with the C3 protein, the B-factor fragment Bb (yellow), and
the surface of a pathogen (hexagon). These interactions lead to the C5
protein and the MAC formation [14].
Released complement protein fragments such as C3a and C5a sti-
mulate mast cells, granulocytes and macrophages, which can sig-
niﬁcantly contribute to cardiovascular distress [15–17]. The particle
morphology can play a decisive role in preventing phagocytosis pro-
cesses [18,19] like those ones mediated by pulmonary intravascular
macrophages as it has been recently discussed [20].
The activation of the immune system may lead to an adverse im-
mune phenomenon known as complement activation-related pseudo-al-
lergy (CARPA) [21]. CARPA is used to describe acute hypersensitivity
reactions (HSRs) to nanomedicines occurring in up to 45% of in-
dividuals [22]. In some individuals, these HSRs can be severe or even
fatal [23]. It has been proposed that pigs can provide a sensitive,
quantitative, and biologically relevant animal model of severe human
CARPA [24–28]. The main manifestation of CARPA is cardiopulmonary
distress, caused by pulmonary hypertension, which is critical for pa-
tients suﬀering from cardiac pathologies [23]. It leads to changes in
pulmonary arterial pressure (PAP) and systemic arterial pressure (SAP)
[26,29,30]. Due to this potential reactivity, the European Medicines
Agency recommends in vitro and in vivo assessments of CARPA as a
preclinical immune toxicity test in the development of liposomal drugs
[31]. Detection and prevention of CARPA at an early stage of nano-
medicine research is one of the strategies to successfully develop na-
nopharmaceutics. Liposomal drugs that cause CARPA have been re-
ported previously [21,32]. Phospholipid bilayers can activate the
complement system, and, among other factors, size, shape, lipid com-
position, and presence of surface charges are all sources for complement
activation by liposomes in vitro[15,23,24]. Therefore, one step on the
road to testing shear-responsive Pad-PC-Pad liposomes clinically is the
evaluation and minimization of their risk for HSRs.
In the present communication, we hypothesize that Pad-PC-Pad lipo-
somes, containing PEGylated lipids and nitroglycerin, hardly trigger CARPA.
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Fig. 1. Main steps of the complement activation cascade.
The identiﬁcation of the SC5b-9 complex (light blue-co-
lored box) through the three pathways provides an insight
into understanding the interaction between Pad-PC-Pad
liposomes and the immune system. The classical pathway
(yellow-colored box) is mediated by an antigen-antibody
complex, whereas the lectin pathway (also a yellow-co-
lored box) and the alternative pathway (gray-colored box)
are initiated at the pathogen surfaces. (For interpretation
of the references to colour in this ﬁgure legend, the reader
is referred to the web version of this article.)
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We know that the activation of the complement system causes the
formation of the lytic C5b-9 complex bound to the S protein. The
concentration of the soluble C5b-9 (SC5b-9) protein complex was in-
vestigated in vitro, using an enzyme-linked immunosorbent assay
(ELISA). Herein, human or animal sera were incubated together with
the liposomal drug.
For the negative control, each donor's serum was treated with saline
(liposome buﬀer) or nitroglycerin (liposome payload). For the com-
parison with established liposomal drugs and the positive control, each
donor's serum was treated with Doxil, Abelcet, and zymosan. Doxil is
widely used in cancer treatment and consists of PEGylated liposomes
below 100 nm in size, encapsulating doxorubicin as the active drug
[33]. Abelcet is one of the three commercially available lipid for-
mulations containing amphotericin B, which is used to ﬁght against
systemic fungal infections. It consists of ribbon-like complexes 1 to
10 μm in size [34]. Zymosan, a well-known complement activator, is a
bacterial glucan applied in experiments to quickly induce inﬂammation
and complement activation [35]. Samples containing the human sera
were subjected to SC5b-9 level detection. Furthermore, the three pos-
sible pathways, through which the MAC can be formed, were in-
vestigated individually through the detection of proteins within the
complement cascade including C4d (classical and lectin pathways) and
Bb (alternative pathway) protein concentrations. In porcine sera,
complement activation was evaluated via C3 protein consumption. In
vivo, the immune system response was investigated by intravenous in-
jection of liposomes into pigs with continuous monitoring of the he-
modynamic and hematological changes.
2. Materials and methods
2.1. Materials
A 0.1% commercially available nitroglycerin solution (Perlinganit,
UCB-Pharma AG, Bulle, Switzerland, and Nitroglycerin Bioren 0.1%,
Sintetica, Mendrisio, Switzerland) was used. PEGylated DSPE (DSPE-
PEG2000) was a gift from Lipoid (Ludwigshafen, Germany). Zymosan,
chloroform, and methanol were purchased from Merck p.a. (Darmstadt,
Germany) and Sigma-Aldrich Chemie GmbH (Buchs, Switzerland).
Doxil (Janssen-Cilag International NV, Beerse, Belgium) and Abelcet
(Teva Pharmaceutical Works Ltd.) were used as purchased. Saline so-
lution (0.9% NaCl, 308 mOsm/L) was purchased from Teva
Pharmaceutical Works Ltd. (Budapest, Hungary) and Bichsel AG
(Interlaken, Switzerland). All chemicals were of pharmaceutical grade
and used without further puriﬁcation.
Human serum samples of healthy volunteers were obtained ac-
cording to the institutionally approved phlebotomy protocol at the
Semmelweis University (Budapest, Hungary). Porcine sera were pro-
vided by the Institute of Animal Breeding and Nutrition Research
Institute (Herceghalom, Hungary). All the sera were stored at a tem-
perature of −80 °C until use.
2.2. Lipid synthesis
Pad-PC-Pad (1,3-palmitoylamido-1,3-deoxy-sn-glycero-2-phosphati-
dylcholine) was prepared following the reported protocol [11,36].
Brieﬂy, starting from 1,3-dichloropropan-2-ol, the protected phosphate
head group was introduced by using phosphoryl chloride, N-Boc-ami-
noethanol, and ammonium hydroxide. Subsequent treatment with so-
dium azide led to the substitution of both chlorides. A Staudinger-type
reduction of the resulting bis-azide yielded the free bis-amine.
Using a Schotten-Baumann-type protocol with palmitoyl chloride,
fatty acyl chains were introduced. Finally, the head group was de-
protected and quarternized, yielding Pad-PC-Pad. The product was
puriﬁed sequentially by silica gel column chromatography (silica
63–200, 60 Å, Chemie Brunschwig AG, Basel, Switzerland), using a
mixture of chloroform, methanol, and water (65:25:4 v/v/v), by pre-
cipitation in cold acetone, and by size exclusion chromatography on
Sephadex LH-20 (GE Healthcare Biosciences, Uppsala, Sweden), using a
mixture of chloroform, methanol, and water (65:25:4 v/v/v).
2.3. Liposome preparation
The phospholipids were dissolved in chloroform in molar ratios as
described in Table 1: L1 and L2 contained Pad-PC-Pad and DSPE-
PEG2000, while L3 was formulated from Pad-PC-Pad only. The three
liposomal formulations were prepared via the standard thin ﬁlm
method [37,38], and they were either hydrated with saline solution, in
the case of L2, or passively loaded with commercially available ni-
troglycerin, in the cases of L1 and L3. Each suspension was prepared in
order to get a ﬁnal lipid concentration of 20 mg/mL, the highest con-
centration achievable using the Pad-PC-Pad lipids. The suspensions
were freeze-thawed in a twelve-step series: Frozen in liquid nitrogen
and heated in a 60 °C water bath. In order to get a size distribution of
around 100 nm in diameter, each liposomal suspension was downsized
by multiple barrel extrusions using Liposofast LF-50 (Avestin Inc., Ot-
tawa, Canada) through track-edged polycarbonate ﬁlter membranes
(Whatman Nucleopore, Sigma-Aldrich, Buchs, Switzerland) of selected
pore sizes: 400 nm (ﬁve times), 200 nm (ﬁve times), and 100 nm (15
times). The non-encapsulated nitroglycerin in the L1 and L3 suspen-
sions was removed by buﬀer exchange, using PD-10 desalting columns
with 5000 Da size exclusion limit, following the manufacturer's gravity
protocol (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). In the in
vitro experiments, the ten-fold diluted counterparts of L1, L2, and L3
were tested and labeled ‘L1a’, ‘L2a’, and ‘L3a’, respectively. The dilution
was carried out using saline solution.
For the in vivo experiment, three batches of liposomes, labeled L1′,
L2′, and L3′, were prepared using the same lipid composition as L1, L2,
and L3, respectively (cf. Table 1), and by following the protocol de-
scribed above. For the samples L1′ and L3′, Perlinganit was used as a
drug, whereas the sample L2′ comprised drug-free liposomes. Lipid
content was obtained by the phosphate test 2.0 [39]: 12 mg/mL for L1′,
16 mg/mL for L2′, and 11 mg/mL for L3′. All the liposomal suspensions
were stored at room temperature until use.
2.4. Liposome characterization
Lipid content in the liposomal suspension was determined after
puriﬁcation by phosphate test 2.0 [39]. Brieﬂy, liposome concentration
was calculated from the measured phosphate content (phosphate
moiety in the head group of the phospholipids): An aliquot (20 μL) of
the liposome suspension was diluted with ultrapure water (180 μL,
18.2 MΩcm) in a 0.5 to 2 mL microwave vial (Biotage, Stockholm,
Sweden). Then, 500 μL of a mixture (3/1 v/v) of nitric acid (65% Reag.
ISO, Reg. Ph. Eur. grade, Honeywell, Morristown, USA) and sulfuric
acid (95% Reag. ISO, Reg. Ph. Eur. grade, Honeywell, Morristown,
USA) was added. The vial was sealed and heated in a microwave to a
temperature of 180 °C for a period of 20 min (Biotage Initiator,
Table 1
Liposomal suspensions tested in vitro and in vivo.
Label Lipid composition (molar %) Load
In vitro In vivo Pad-PC-Pad DSPE-PEG2000
L1, L1aa L1′ 95 5 Nitroglycerin
L2, L2aa L2′ 95 5 Bare
L3, L3aa L3′ 100 – Nitroglycerin
a Liposomal suspension diluted ten times using saline solution.
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Stockholm, Sweden). The vial was allowed to cool down and the fol-
lowing solutions were added in sequence: Water (2.3 mL), ammonium
metavanadate and ammonium heptamolybdate coloring agent (1 mL),
and sodium hydroxide solution (10 M, 1 mL). The solution was allowed
to rest for ten minutes. The solution was then pipetted into a 96-well
plate (Nunc-Immuno plate F96 Polysorb, Roskilde, Denmark), using a
multi-channel pipette (eight times 300 μL), and the absorbance was
measured at a wavelength of 405 nm, using a plate reader (MultiskanFC
96 from Thermo Scientiﬁc, Waltham, USA).
Furthermore, the size of the liposomes, including the polydispersity
index (PDI), was obtained by dynamic light scattering (DLS), using a
Delsa Nano C (Beckman Coulter, Brea, USA). DLS measurements were
performed at a temperature of 25 °C, using two laser diodes working at
a wavelength of 658 nm. The scattering angle was set to 165 degrees.
The zeta (ζ) potential of the liposomal formulations was determined
by laser Doppler micro-electrophoresis, using a Zetasizer Nano-ZS
(Malvern Instruments Ltd., Malvern, UK). The measurements were
carried out at a temperature of 25 °C, using a wavelength of 633 nm.
The scattering angle was set to 173 degrees, using non-invasive back-
scattered (NIBS) optics. The experimental data were treated according
to the Smoluchowski equation.
The suspensions were diluted 30 times with saline prior to both DLS
and ζ potential measurements.
Transmission electron microscopy (TEM) images of the three lipid
formulations were obtained at cryogenic temperatures. Prior to the
measurements, the three liposomal suspensions were diluted to a con-
centration of 5 mg/mL and were mounted on glow-discharged holey
carbon grids, quickly frozen by a Cryoplunge CP3 system (Gatan Inc.,
Pleasanton, USA), and transferred to a JEM2200FS transmission elec-
tron microscope (JEOL Ltd., Tokyo, Japan) using a Gatan626 cryo-
holder. Cryo-electron micrographs were recorded at an acceleration
voltage of 200 kV at a magniﬁcation of 20,000, 4 to 8 μm under-focus,
and a dose of 10 electrons/Å2, using a F416 CMOS detector (TVIPS
GmbH, Gauting, Germany).
The morphology of the liposomes exhibits deviations from the
spherical shape towards ellipsoids, depending on the lipid composition.
The local curvature C and the eccentricity ε of the liposomes were es-
timated from the cryo-TEM projections (cf. Fig. 2). Therefore, ellipses
have been employed with a and b the major and minor semi-axes. The
curvature of an ellipse can be written as C= a b / (a2 sin2 (t) + b2 cos2
(t))3/2 being t the angle between a and a generic point lying on the
ellipse. For sphere-like liposome a= b= r, the curvature is given by
Ccircle = 1/r, being r the outer radius of the ﬁtted circle. In case of an
elliptically shaped liposome, the local curvature Cellipse ranges from b/
a2 to a/b2. The eccentricity of an ellipse is given by = −ε b a1 2 2 and
ranges as 0 < ε < 1; for circles it is zero.
The eﬃciency of nitroglycerin loading was estimated indirectly
from the glucose content of the nitroglycerin solution measured by
electrospray ionization mass spectrometry (ESI-MS) using a Bruker
Daltonics esquire HCT ion trap mass spectrometry [40]. Here, a volume
of 0.1 mL of each sample was diluted ten times with methanol and
treated with 10 μL of triﬂuoroacetic acid. The ESI spectra were mea-
sured in the negative mode. The ESI-MS signal of the observed glucose-
triﬂuoroacetic acid adduct at 292.92 amu was compared to the ESI-MS
signal which an equally treated solution of nitroglycerin (Bioren 0.1%
containing 1 mg/mL nitroglycerin as active pharmaceutical ingredient
and 49 mg/mL glucose as excipient) yields. It was assumed that the
ratio of glucose versus nitroglycerin, as found in the commercial ni-
troglycerin solution, stays constant during the liposome formulation
and puriﬁcation steps.
2.5. In vitro immunoassay in human sera via SC5b-9
Human sera from six donors were aliquoted and stored in Eppendorf
tubes at a temperature of −80 °C. Prior to use, they were thawed to
4 °C and kept in an ice bath. Each human serum was mixed with the
three liposomal suspensions (L1, L2, and L3) and their ten-times diluted
counterparts (L1a, L2a, L3a). Each serum was treated with saline and
nitroglycerin solution being the negative controls. For the comparison
with FDA-approved liposomal drugs and as positive control, mixtures of
each serum with Doxil (2 mg/mL doxorubicin, 12.7 mg/mL phospho-
lipids), Abelcet (5 mg/mL amphotericin B, 4.9 mg/mL phospholipids),
and zymosan (1.5 mg/mL) were used. Each mixture was incubated at a
temperature of 37 °C. The reaction was terminated after 5, 10, 20 and
40 min by adding 10 mM ethylenediaminetetraacetic acid (EDTA,
Sigma-Aldrich Kft, Budapest, Hungary). The level of SC5b-9 was
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Fig. 2. Structure of the two phospholipids used for the liposome preparations: Pad-PC-Pad (1) and DSPE-PEG2000 (2). Cryo-TEM micrographs of L1 Pad-PC-Pad/DSPE-PEG2000/
nitroglycerin (left), L2 Pad-PC-Pad/DSPE-PEG2000/saline (middle), and L3 Pad-PC-Pad/nitroglycerin (right) liposomes. The pure Pad-PC-Pad liposomal suspension contains many
aggregated clusters, possibly because the stiﬀ membranes lack repulsive undulation movement. The curvature C of the liposomes was estimated: (51 nm)−1 to (44 nm)−1 for L1,
(130 nm)−1 to (10 nm)−1 for L2, and (100 nm)−1 to (5 nm)−1 for L3.
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quantiﬁed by a MicroVue SC5b-9 Plus ELISA kit (Quidel, San Diego,
USA). The assay was carried out following the manufacturer's protocol.
Classical and alternative pathways were tested using the MicroVue C4d
Plus ELISA and MicroVue Bb Plus ELISA kits (Quidel, San Diego, USA),
to detect the concentration of C4d and of Bb, respectively. The samples
prepared for SC5b-9, C4d, and Bb assays were diluted 20 times using
the specimen diluent provided by the SC5b-9 kit and additional 10 mM
EDTA, as the minimum dilution required to detect the optical density.
The lectin pathway was investigated using samples treated as described
above and supplemented with EGTA/Mg2+ (Ca2+ chelation), in order
to block selectively the classical pathway [41]. In this case, the Mi-
croVue C4d Plus ELISA assay was used to detect C4d concentration.
After termination of the reaction, the samples were diluted 30 times
with the specimen diluent provided by the C4d kit and additional
10 mM EDTA. Each sample was subjected to a further dilution step
before transferring it to the ELISA plate. The optical density was mea-
sured with a 96-well plate reader (FLUOstar Omega, BMG Labtech,
Ortenberg, Germany) at a wavelength of 450 nm (in the cases of SC5b-9
and Bb) and at a wavelength 405 nm (in the case of C4d).
2.6. SC5b-9 detection in porcine sera via C3 consumption
In a previous study [42], we tested complement activation in por-
cine samples, using the MicroVue Pan-Speciﬁc C3 Reagent Kit (Quidel,
San Diego, USA). This test, however, is rather qualitative for a study
involving porcine sera, because validity has only been demonstrated for
human sera. Therefore, we searched for an alternative kit to measure
directly the concentration of the SC5b-9 complex in porcine sera. We
identiﬁed the ELISA kits from MyBioSource Inc. (San Diego, USA) as
being possibly suited to this purpose. The manufacturer states that the
kit is a quantitative sandwich ELISA assay, to be used for determining
the level of SC5b-9 in undiluted original porcine body ﬂuids. Following
the guidelines of the manufacturer concerning sample preparation and
the assay procedure, we did not ﬁnd any signiﬁcant diﬀerence between
the negative (phosphate-buﬀered saline) and positive (zymosan) con-
trols. As there was no support available from the supplier, we have to
state that the kit was inappropriate for our study. Thereafter, we
decided to investigate the level of SC5b-9 in porcine sera through the
qualitative detection of C3 consumption, using a MicroVue Pan-Speciﬁc
C3 Reagent Kit from Quidel Corp., which, to the best of our knowledge,
is the only possibility currently available on market.
Each donor's serum was treated with the liposomes, the positive and
negative controls as done with the human ones, see description in
Section 2.5. As stated above, complement activation in porcine samples
was assessed using the Quidel MicroVue Pan-speciﬁc C3 reagent kit.
This kit allowed for converting the C3 activity in animal samples to the
human SC5b-9 protein complex, which could be detected using the
SC5b-9 Plus ELISA kit. The optical density was measured with a 96-well
plate reader (FLUOstar Omega, BMG Labtech, Ortenberg, Germany) at a
wavelength of 450 nm.
2.7. Statistical analysis
The statistical analysis was carried out using GraphPad Prism 6
(GraphPad Software Inc., San Diego, USA). All samples, except those
incubated with zymosan, were compared with saline after 40 min of
incubation, using ordinary one-way ANOVA, followed by Dunnett's
multiple comparison test. P-values lower than 0.05 were considered as
statistically signiﬁcant.
2.8. CARPA in the porcine model
Six domestic male, mixed breed Yorkshire-Hungarian landrace pigs,
weighing from 19 to 24 kg, were treated according to the protocol
approved by the local Animal Subject Review Committees. Animals
were pre-anesthetized intramuscularly with Calypsol/Xilazine 2–3/
1.5–2 mL/kg injections in the stalls, to avoid stress, and further an-
esthesia was maintained with 2 to 3% isoﬂurane in O2. Intubation was
performed with endotracheal tubes to maintain open airways and to
enable controlled ventilation. Spontaneous ventilation was followed by
a pulse-oximeter ﬁxed on the tail to monitor oxygen saturation.
Temperature was measured rectally and monitored by an Innocare-P
anesthesia monitor. A capnograph was connected to the tracheal tube to
monitor end tidal CO2 and respiratory rate (CAP10 Medlab,
Medizinische Diagnosegeräte GmbH, Karlsruhe, Germany). Surgery was
done after povidone iodine (10%) sterilization of the skin. In order to
measure the PAP, a Swan-Ganz catheter (AI-07124, 5 Fr. 110 cm, Arrow
International Inc., Reading, USA) was introduced into the pulmonary
artery via the right external jugular vein, while the SAP was measured
in the femoral artery. Blood samples were taken from the left femoral
vein, before and after the injection of liposomes (time points after 1, 3,
5, 10, 20, and 30 min), and were collected in hirudin- and K2-EDTA
tubes. Liposome suspensions and zymosan were injected into the ani-
mals as bolus within a period of< 10 s via the left external jugular
vein. Hemodynamic changes (PAP, SAP, and heart rate (HR)) were
continuously monitored and either expressed in absolute or in relative
terms compared to the baseline throughout this study.
3. Results
3.1. Liposome characterization
The total lipid concentration was measured after puriﬁcation and
found to be (20.40 ± 0.16) mg/mL for L1, (16.52 ± 0.10) mg/mL for
L2, and (18.72 ± 0.03) mg/mL for L3. Table 2 lists the related DLS and
ζ potential results. Within the estimated errors, the results for the li-
posomes with and without PEGylated lipids were comparable. The
measured eccentricity ε of the three liposomal formulations ranged
from zero to 0.95 (Table 2); the curvature C was estimated (Fig. 2,
caption). Preliminary data of the nitroglycerin incorporation eﬃciency
measured by ESI-MS showed 49% for L1 and 27% for L3. These results
indicated a beneﬁcial eﬀect of the presence of PEG network for re-
taining nitroglycerin inside a liposome.
Fig. 2 displays cryo-TEM images representing the morphology of the
liposomes. Pure Pad-PC-Pad liposomes formed aggregates (Fig. 2,
right), probably due to limited membrane ﬂexibility. Membrane un-
dulation typically contributes to liposome-liposome repulsive forces
[43], but this aggregation of Pad-PC-Pad liposomes can be prevented by
adding a steric barrier in the form of 5% PEGylated lipids, as indicated
in the other two cryo-TEM images (Fig. 2, left and middle). Cryo-TEM
data further indicated that the liposome suspensions, containing the
PEGylated lipids, were less faceted compared to the liposomes made
Table 2
Characteristics of the liposomal formulations tested in vitro.
Label Lipid composition Lipid content
(mg/mL)
Mean diameter
(nm)
PDI Eccentricity ζ potential
(mV)
εmin εmax
L1 Pad-PC-Pad/DSPE-PEG2000 (nitroglycerin) 20.40 ± 0.16 122 ± 2 0.09 ± 0.01 0 0 −0.78 ± 0.18
L2 Pad-PC-Pad/DSPE-PEG2000 (bare) 16.52 ± 0.10 151 ± 2 0.21 ± 0.03 0.40 ± 0.01 0.91 ± 0.01 −1.78 ± 0.14
L3 Pad-PC-Pad (nitroglycerin) 18.72 ± 0.03 166 ± 9 0.19 ± 0.03 0.47 ± 0.01 0.95 ± 0.01 −0.60 ± 0.15
M. Buscema et al. Journal of Controlled Release 264 (2017) 14–23
18
71
from pure Pad-PC-Pad, and the addition of nitroglycerin reduced the
faceting of the liposomes, cf. Fig. 2. The diameters of liposomes derived
from the cryo-TEM images were in agreement with those from the DLS
data.
3.2. In vitro immunoassay in human sera
Fig. 3 shows the concentration of the protein C4d, without (A) and
with (B) the addition of EGTA/Mg2+, Bb (C), and the terminal complex
SC5b-9 (D) tested in human sera from six donors. The sera were in-
cubated with the liposomes or the appropriate controls for a period of
40 min. As the experimentally found lipid contents of the three lipo-
somal formulations corresponded to (20.40 ± 0.16) mg/mL for L1,
(16.52 ± 0.10) mg/mL for L2, and (18.72 ± 0.03) mg/mL for L3, the
obtained data were adjusted to the liposome concentration of 20 mg/
mL, in order to mitigate the eﬀect of the lipid concentration on the
complement protein levels. Thus, the data were multiplied by the factor
0.98 for L1, 1.21 for L2, and 1.07 for L3. The phosphate test and the
DLS results enabled us to estimate the average liposome-entrapped
volume, which was 61.7 μL per mL suspension for L1 and 91.4 μL per
mL suspension for L3. According to the ESI-MS results, being the en-
capsulation eﬃciency 49% for L1 and 27% for L3, the total amount of
nitroglycerin per mL suspension was 30.4 μg for L1 and 24.6 μg for L3.
The diagrams in Fig. 3A and B provide the results of the classical
and lectin pathways, respectively. For the lectin pathway, the C4d level
of the sample containing Abelcet was not available. The C4d con-
centration of the samples did not show any signiﬁcant diﬀerence
compared to saline. The only exception was zymosan, where a slight
increase in C4d concentration was observed, as illustrated in the dia-
gram of Fig. 3A.
Bb concentrations, see Fig. 3C, in the samples containing Abelcet
and zymosan increased four- and eight-fold with respect to saline. For
the liposomal suspensions L1 and L2, Bb concentration was found
comparable to Doxil and more than twice that of saline. Liposome
suspensions at a lower phospholipid content (L1a, L2a, and L3a), as
well as L3, did not show any signiﬁcant increase in Bb level with respect
to saline.
The three pathways can lead to the formation of the terminal
complement complex detected by soluble C5b-9 concentration in the
serum. Fig. 3D displays the results with respect to the SC5b-9 con-
centration. It was found that zymosan activated the formation of the
SC5b-9 complex within only ﬁve minutes of incubation, cf. Supple-
mentary information, Fig. S1, and increased up to 80 times after 40 min
of incubation as compared to saline. Abelcet increased SC5b-9 con-
centration> 15 times compared to saline. SC5b-9 concentration in the
liposomal suspensions L2 and L3 increased ﬁve-fold compared to Doxil
and ten-fold compared to the negative control, whereas L1 showed
more than seven times and 15 times higher SC5b-9 levels compared to
saline and Doxil, respectively. At a lower phospholipid concentration,
i.e. L1a, L2a, and L3a, the level of SC5b-9 increased less than twice the
amount of saline and, within the standard deviation, the results were
comparable to Doxil.
The controls and the liposomes were also incubated with each
human serum for 5, 10, and 20 min. These data at the selected time
points show a trend summarized in Supplementary information, Fig. S1.
3.3. Validation of the in vitro human sera study
The results of the in vitro study using human sera were underpinned
by the in vitro assessment of complement activation with porcine sera
from six animals, and the in vivo experiment with continuous mon-
itoring of the hemodynamic behavior of six Yorkshire pigs after the
injection of Pad-PC-Pad liposomes.
3.3.1. In vitro immunoassay in porcine sera
The level of complement activation in porcine sera from six animals,
tested through C3 consumption, is displayed in Fig. 4. The sample
containing saline was used as a baseline. The level of C3 consumption in
Abelcet increased up to 72% over the baseline and was twice that of
zymosan. Doxil led up to a 20% increase, showing similar complement
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Fig. 3. The level of C4d (A), of C4d supplemented by
EGTA/Mg2+ (B), of Bb (C), and of SC5b-9 (D) from human
sera of six donors incubated for a period of 40 min at a
temperature of 37 °C with saline, nitroglycerin (NTG), li-
posomes containing low (L1a, L2a, L3a) and high (L1, L2,
L3) lipid contents, Doxil, Abelcet, and zymosan. The data
are presented as mean values, including error bars derived
from the standard deviation among the sera. Each symbol
(triangle, square, circle, star, cross, rhombus) represents
data from one of the six donors. The values were adjusted
to the liposome concentrations of 2 and 20 mg/mL, re-
spectively. For the statistical analysis, zymosan was ex-
cluded.
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activity as in L1 and L2 with 22% and 20% rises over saline, respec-
tively. Lower levels of C3 consumption were found for L3 and L3a - an
increase of< 10% – and even less for L1a and L2a with increases over
the baseline of 4% and 3%, respectively. According to the statistics,
signiﬁcant diﬀerences with respect to saline were only found for the
undiluted sample containing Pad-PC-Pad/DSPE-PEG2000 loaded with
nitroglycerin (L1) and for Abelcet.
3.3.2. In vivo study in the porcine model
Six pigs were used to explore in each the hemodynamic changes
caused by sequential intravenous administrations of selected liposome
boluses, as speciﬁed in Tables 3 and 4. L1′ was tested in three doses. L2′
and L3′ were injected using a pre-deﬁned dose in the six animals. At the
end of each experiment, zymosan was injected as positive control. The
sequences, with which the liposomal formulations were injected, are
represented in Supplementary information, see Table S2.
The human therapeutic dose (HTD) of intravenous nitroglycerin so-
lution ranges from 13 to 133 μg in one minute [44,45]. The liposome
doses were adjusted in order to obtain 0.5 mg Pad-PC-Pad per kg of pig
and ﬂushed into the circulation with 5 mL saline solution. Therefore, the
total amounts of phospholipids for the samples containing PEGylated
lipids (L1′, L2′) were 0.6 mg/kg (0.5 mg/kg Pad-PC-Pad plus 0.1 mg/kg
DSPE-PEG2000) for HTD. Using the same lipid formulation as in L1′,
another two nitroglycerin dosages were prepared: 0.33 × HTD and
3 × HTD with a total concentration of 0.2 mg/kg (0.17 mg/kg Pad-PC-
Pad plus 0.03 mg/kg DSPE-PEG2000) and 1.8 mg/kg (1.5 mg/kg Pad-
PC-Pad plus 0.3 mg/kg DSPE-PEG2000), respectively. According to ESI-
MS measurements the dose of nitroglycerin was 94 μg per minute for L1′
and 79 μg per minute for L3′, in agreement with the HTD. As the injec-
tion time of the liposomal suspension was about 10 s, the nitroglycerin
payload was 0.8 μg per kg pig for L1′ and 0.7 μg per kg pig for L3′.
As expected, the injection of liposomal drugs led to HR modiﬁca-
tion, a PAP increase, and a change of SAP. In one of the six pigs, the L1′
injection led to a slight increase of HR, which returned to baseline level
within minutes. All other samples did not cause any visible change of
the HR, besides the gradual, slow increase of the HR during the course
of the experiment, owing to anesthesia. Moreover, no cardiac ar-
rhythmia in the form of tachycardia or bradycardia, or extrasystoles,
was observed.
Changes in PAP and SAP observed upon injecting the liposomes
were calculated as relative changes in percentage terms of the baseline
value at pre-injection time. An overview of the recorded PAP, SAP, and
HR graphs upon injection of Perlinganit-loaded and drug-free liposomes
is represented in the Supplementary information, see Figs. S2 to S7.
The zymosan injection always led to an immediate PAP increase of
up to 180%. The injection of 70 μg nitroglycerin, however, caused a
decrease in the PAP of maximal 25%. These results set the stage for
assessing the CARPA caused by the liposomal suspensions.
The measured maximal changes in PAP upon injecting the corre-
sponding liposomal formulations are listed in Table 3. In all cases,
sample L1′ with 1.5 mg/kg of Pad-PC-Pad showed an increase of the
PAP of up to 76%, thus indicating mild complement activation. This
increase is similar to the hemodynamic changes that occurred following
an injection of Doxebo liposomes [25]. Compared to other liposomal
drugs, such as Ambisome, where the PAP increases by 200% for an
injection of 0.01 mg/kg [27], or Doxil, with an increase up to 400% of
the baseline [25] for 0.06 mg/kg phospholipid, the observed increase in
PAP with liposomes encapsulating nitroglycerin also had a minimal
eﬀect of about a 33% increase in PAP, most likely caused by the ag-
gregation of liposomes [42]. Furthermore, it should be noted that it is
only the response to the ﬁrst injection where cumulative eﬀects can be
excluded. In fact, self-induced tolerance, i.e., tachyphylaxis has been
known in case of certain liposomes. However, the fact that we saw
reactions to the second and third boluses of L1′ argued against full ta-
chyphylaxis after the ﬁrst injection, enabling us to test L2′ and L3′ at the
same doses as L1′ was ﬁrst injected (0.5 mg/kg). The presence of very
similar, small reactions to L2′ and L3′ cannot be explained by tachy-
phylaxis, as tachyphylaxis prevents follow-up reactions to identical
doses, and L1′ was applied three times at much higher doses, which
would fully eliminate any further reaction in the presence of tachy-
phylaxis. Partial tachyphylaxis cannot be ruled out, but overall, these
pig data showed very mild changes, which are most likely biologically
irrelevant. However, the mere presence of even small hemodynamic
changes point to a risk of CARPA in case of substantial overdosing of
test liposomes.
3.3.3. Tachyphylaxis in pigs after Pad-PC-Pad injection
PAP usually increased after the ﬁrst liposome injection. The reaction
to a subsequent injection showed possible tachyphylaxis. An example of
the PAP response is represented in Fig. 5 regarding the injection re-
gimes, with the injection sequence being modiﬁed for samples L1′
through L3′. The upper panel on Fig. 5 displays PAP changes in a se-
lected animal, induced by injecting the L1′ samples in order of in-
creasing concentration, starting with the lowest lipid concentration of
0.17 mg/kg and ﬁnishing with the highest one of 1.5 mg/kg. The PAP
always reached the same level. Changes in PAP monitored in another
animal are shown in the lower panel in Fig. 5. When the highest
phospholipid concentration was injected ﬁrst, partial tachyphylaxis was
observed.
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Fig. 4. Complement activation through C3 protein consumption relative to saline in
porcine sera from six diﬀerent animals incubated for a period of 40 min at a temperature
of 37 °C with saline and nitroglycerin (NTG), liposomes containing low (L1a, L2a, L3a)
and high (L1, L2, L3) lipid contents, Doxil, Abelcet, and zymosan. The data are shown as
mean values, including standard deviation among animals. Each symbol (triangle, square,
circle, star, cross, rhombus) represents data from one porcine serum. The values were
adjusted to liposome concentrations of 2 and 20 mg/mL, respectively. For the statistical
analysis, zymosan was excluded.
Table 3
Relative maximal changes in pulmonary arterial pressure. Bolus injections were separated
by at least 30-minute recovery periods. Lipid concentrations correspond to the amounts of
Pad-PC-Pad per kg (of pig). The sequence of liposomal injection is given in Supplementary
information (Table S2).
Pig ID L1′
0.5 mg/kg
1/3 × L1′
0.17 mg/kg
3 × L1′
1.5 mg/kg
L2′
0.5 mg/kg
L3′
0.5 mg/kg
PAP (%)
1 14.9 17.7 16.9 4.7 3.5
2 NA 3.5 30.4 8.1 0.0
3 1.9 NA 75.9 2.9 0.0
4 0.0 NA 19.4 8.5 1.5
5 6.3 NA 7.2 NA 4.2
6 6.0 4.8 32.7 1.7 10.1
Mean ± SD 5.8 ± 5.7 8.7 ± 7.9 30.4 ± 24.2 5.2 ± 3.0 3.2 ± 3.8
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3.3.4. Changes in systemic arterial pressure (SAP)
The extrema of the systemic arterial pressure measurements are
listed in Table 4. Contrary to the consistent rise in PAP, SAP showed an
immediate increase or decrease of up to 10% for the 0.1 mg/kg zy-
mosan injection, with the type of reaction depending on the individual
pig. The injection of 70 μg nitroglycerin caused a maximal decrease of
10% in SAP level. The injection of sample L1′ with 3 × HTD resulted in
a signiﬁcant change in SAP, albeit only for Pig 3.
4. Discussion
Liposome preparation through the extrusion technique is one of the
common methods used to generate uniform liposome suspensions [37].
The mean sizes of the liposomes, being 20% to 70% larger than the
smallest membrane pore size of the ﬁlters used, agrees with previous
ﬁndings [46]. The liposomes of L2 and L3 exhibit a mean size that re-
ﬂects their stiﬀness and degree of faceting. These liposomes were ex-
truded above the membrane main phase transition temperature to fa-
cilitate sizing. Nonetheless, parts of the rather stiﬀ membranes of L2
and L3 passed the extrusion ﬁlter pores without being sheared, possibly
by adopting an orientation along the ﬂow direction.
The ζ potential measurements characterize liposome surfaces and
the stability of suspensions, both of which are essential for the eﬃcacy
of drug delivery [47]. It has been reported that the presence of
PEGylated lipids aﬀects ζ-potential, which depends on PEG size and
anchor [27,48]. Our results show ζ-potential values close to zero, re-
gardless of PEGylation (Table 2). This behavior can be explained by
Pad-PC-Pad resulting in a neutral, zwitter-ionic amphiphile (Fig. 2, (1)).
The addition of negatively charged DSPE-PEG2000 causes the expected
marginal decrease in the ζ-potential, as the comparison between L1 and
L3 indicates. Encapsulated nitroglycerin has a detectable impact, be-
cause the liposomes prepared in saline (L2) show a ζ-potential which is
more than twice as high as the value of the formulations with ni-
troglycerin, i.e. L1 and L3.
Due to its simplicity, the passive loading of a drug into a liposome
via thin lipid ﬁlm hydration and freeze-thaw steps is widely used. The
presence of a PEG network inside and outside of the liposome mem-
brane in the formulations L1 and L2 was solely chosen to prevent the
formation of aggregates, which increase the immune system response
[42]. Furthermore, the addition of PEGylated lipids seemed to be
beneﬁcial to nitroglycerin retention and suggests a noncovalent inter-
action between the two molecules.
A semi-quantitative ESI-MS assay, carried out for the liposomal
formulation L1 and L3, showed a high loading of 27% to 49% ni-
troglycerin into Pad-PC-Pad liposomes, respectively. The passive
loading of nitroglycerin is higher than expected from literature data of
passive loading of other drug molecules [49], possibly because of the
low nitroglycerin molecular weight being 227.1 Da.
The present study identiﬁed the pathway, through which Pad-PC-
Pad-based liposomes can trigger the complement system. Although the
in vitro results of the immunoassay in human sera clearly indicate no
activation of the lectin pathway, the result has to be treated with care,
because for the lectin pathway test the sample containing Abelcet was
unavailable. The classical pathway, however, can deﬁnitely be ruled
out, as zymosan exhibited the expected rise. The predominant role of
the alternative pathway with respect to its classical and lectin coun-
terparts in the presence of PEGylated lipids (L1 and L2 vs. L3) agrees
with information available in the literature [27,48].
Samples containing Abelcet activated the complement system via
the alternative pathway stronger than Doxil and Pad-PC-Pad-based li-
posomes at both high and low phospholipid contents. This enhanced
complement activation is possibly associated with the micrometer size
of the lipid complexes loaded with the amphotericin B drug. A previous
communication [23] reported that larger liposomes increase the risk of
severe immune reactions.
It is not surprising that Pad-PC-Pad-based liposome suspensions L1a,
L2a, and L3a show a SC5b-9 level similar to the Doxil sample. This
behavior is supported by the fact that these liposomes exhibit a size of
about hundred nanometers. These formulations caused mild comple-
ment activation. In particular, the L1 formulation, comprising Pad-PC-
Pad, PEGylated lipid, and the nitroglycerin payload, could trigger the
immune system. This fact is interpreted as being the result of ampliﬁ-
cation caused by combining PEGylated lipids with nitroglycerin, which
is in agreement with our results. The same behavior is known for Doxil,
as doxorubicin and PEGylated lipids cause a higher response than each
component alone [24]. In addition, it has been reported [23] that the
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Fig. 5. Injection of PEGylated nitroglycerin-loaded Pad-
PC-Pad liposomes in two selected animals. The results for
the ﬁrst animal are represented using ﬁlled black circles
(three diagrams on the upper row) and the ones for the
second animal are given by ﬁlled black squares (three
diagrams on the lower row). Each row represents a con-
secutive injection protocol in one animal. The bolus in-
jections were separated by a recovery time of at least
30 min.
Table 4
Relative maximal changes in systemic arterial pressure. Lipid concentrations correspond
to the amounts of Pad-PC-Pad per kg (of pig). The sequence of liposomal injection is given
in Supplementary information (Table S2).
Pig ID L1
0.5 mg/kg
1/3 × L1′
0.17 mg/kg
3 × L1′
1.5 mg/kg
L2′
0.5 mg/kg
L3′
0.5 mg/kg
SAP (%)
1 0.0 0.8 9.2 4.9 1.0
2 NA −0.4 0.4 2.1 1.5
3 0.0 NA 23.5 0.7 3.5
4 0.0 NA 7.6 2.6 3.3
5 3.6 NA 7.4 NA 2.0
6 1.7 −0.2 5.7 4.9 4.0
Mean ± SD 1.1 ± 1.6 0.1 ± 0.6 9.0 ± 7.7 3.0 ± 1.8 2.6 ± 1.2
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presence of drugs in the liposome's surface and in the medium sur-
rounding the liposomes could increase complement activation.
A previous in vitro study on Pad-PC-Pad liposomes, where the inner
cavity was loaded with phosphate-buﬀered saline, showed negligible
complement activation [42]. The nitroglycerin-loaded Pad-PC-Pad li-
posomes (L1a, L2a, and L3a) yielded a SC5b-9 level, well comparable to
the FDA-approved Doxil, for all tested formulations. Furthermore, C3
protein consumption measured in the sample containing Doxil was
comparable to the formulations L1, L2, and L3, a fact explained by the
higher sensitivity of the immune system in the porcine model with re-
spect to humans.
In the animal experiments, the administration of drug-free (L2′) and
nitroglycerin-loaded (L1′ and L3′) liposomes with dosage up to
3 × HTD highlighted no signiﬁcant changes in the monitored para-
meters, a result which agrees with previous data from liposomes of the
same composition containing phosphate-buﬀered saline [42].
In addition to the complement activation by L1 formulation, which
can be interpreted as being the result of an ampliﬁcation caused by
combining PEGylated lipids with nitroglycerin, the non-faceted shape
of the liposomes has to be considered [13,20]. The cryo-TEM micro-
graphs show that the liposomes prepared with or without the addition
of PEGylated lipid and nitroglycerin payload do not only exhibit a size
distribution but signiﬁcantly diﬀer in shape. As the curvature is size-
and shape-dependent, it is suitable to characterize the liposome's ani-
sotropy by the eccentricity – an approach, which accounts for the recent
interpretation on adverse injection reactions to disk-like and spherical
nanoparticles through shape modiﬁcation [20].
According to the cryo-TEM images, the L3 formulation, where the
highest eccentricity was found (cf. Table 2), caused the lowest com-
plement activation. On the contrary, the L1 formulation comprising
Pad-PC-Pad, PEGylated lipids, and the nitroglycerin payload with zero-
eccentricity triggered a mild complement activation. The formulation
L2 comprising Pad-PC-Pad, PEGylated lipids and loaded with saline
showed eccentricity and complement activation values between the
formulations L1 and L3. Therefore, the shape could be a key parameter
regulating the acute adverse reactions.
Although the identity of the proteins and receptors, that cause the
adverse reactions, remains unknown [20], one may speculate that the
angles oﬀered to the protein adsorption by the non-spherical liposomes
gain access to the underlying phenomena, as found for nanopyramids
inﬂuencing inﬂammatory reactions more than a decade ago [50,51].
Hence, the presence of hydroxyapatite crystallites in bone and the ad-
vantage of nanometer-scale roughness on lead-bearing implants is un-
derstood. In this context, studies on the three-dimensional structure of
Pad-PC-Pad liposomes will follow as a prerequisite for a detailed un-
derstanding of acute adverse reactions.
One limitation of the Pad-PC-Pad liposomes for applications inside
the human body lies in the main phase transition, which is very close to
body temperature. Above 37 °C, the Pad-PC-Pad liposomes release 5(6)-
carboxyﬂuorescein completely [11]. Consequently, for clinical use, one
should search for a slightly more stable mechano-responsive container
than the proposed Pad-PC-Pad liposomes.
5. Conclusion
Nanometer-sized Pad-PC-Pad liposomes with a concentration of
20 mg/mL initiate the complement cascade via the alternative pathway,
concluded from an increase in the level of Bb protein. This ﬁnding is
conﬁrmed by signiﬁcant diﬀerences with respect to saline in the ﬁnal stage
of complement activation, represented by the SC5b-9 concentration, which
has been detected as signiﬁcantly higher than for saline in the ﬁnal stage of
complement activation. Reducing the lipid content of Pad-PC-Pad to 2 mg/
mL, the complement activation was negligible, a result derived from the in
vitro experiments with human and porcine sera as well as an animal study.
Therefore, the liposomes developed in this context are promising me-
chano-responsive container candidates for targeted drug delivery.
Despite the progress in understanding complex processes involving
the immune system defenders, the shape of the particles may play a
basic role in triggering an immune reaction. To this end, the structure of
the liposomes should be better characterized and optimized towards
slightly higher transition temperatures.
Future eﬀorts will focus on the release kinetics of these mechano-
responsive liposomes of 100 nm diameter for a detailed comparison
with currently used non-encapsulated administration methods of ni-
troglycerin in emergency situations.
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Fig. S1. Time point in vitro experiment. SC5b-9 concentration of six human sera incubated at a temperature of 37 °C 
with the positive, negative controls and liposomes at high lipid content (A) and at low lipid content (B). The data are 
shown as the mean value among the six donors. The reaction was terminated after 5, 10, 20, and 40 minutes. The data 
were sorted as A and B, in order to visualize clearly the SC5b-9 level of the Pad-PC-Pad-based liposomes at high and 
low lipid content. 
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Table S2 
Temporal sequences of liposomal injections in the six pigs, from left to right. L1’ was administrated in three liposomal 
concentrations, while L2’ and L3’ in a single concentration. For each injection, the pulmonary arterial pressure, PAP, and 
systemic arterial pressure, SAP, and heart rate, HR, were recorded and displayed in Figures S3 to S8. 
Pig ID 
Injection 
#1 #2 #3 #4 #5 #6 #7 #8 
1 1/3 × L1’ L1’ 3 × L1’ L2’ L3’ Perlinganit zymosan  
2 saline 3 × L1’ L2’ L3’ Perlinganit 1/3 × L1’ zymosan  
3 saline 3 × L1’ L1’ L2’ L3’ Perlinganit zymosan  
4 saline L1’ 3 × L1’ L2’ L3’ Perlinganit zymosan  
5 saline L1’ 3 × L1’ L3’ Perlinganit zymosan   
6 saline 3 × L1’ L1’ 1/3 × L1’ L2’ L3’ Perlinganit zymosan 
  
78 2 Results
  3 
 
Fig. S3. Pig 1 (21 kg male)—Summary: Monitoring of PAP, SAP, and HR changes after injection; dashed line denotes 
injection time. 
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Fig. S4. Pig 2 (20 kg male)—Summary: Monitoring of PAP, SAP, and HR changes after injection; dashed line denotes 
injection time. 
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Fig. S5. Pig 3 (22 kg male)—Summary: Monitoring of PAP, SAP, and HR changes after injection; dashed line denotes 
injection time. 
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Fig. S6. Pig 4 (19 kg male)—Summary: Monitoring of PAP, SAP, and HR changes after injection; dashed line denotes 
injection time. 
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Fig. S7. Pig 5 (19 kg male)—Summary: Monitoring of PAP, SAP, and HR changes after injection; dashed line denotes 
injection time. 
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Fig. S8. Pig 6 (24 kg male)—Summary: Monitoring of PAP, SAP, and HR changes after injection; dashed line denotes 
injection time. 
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The properties of Pad-PC-Pad liposomes have to be tuned to ensure a release of
the drug only at constricted area of diseased blood vessels. For this reason the
morphology of obstructed blood vessels was investigated with particular attention
to the artery lumen, which is inevitably reduced when plaque starts to form.
Synchrotron radiation-based phase µCT provided non-destructive, 3D rendering of
the specimen with suitable contrast for both high (plaque) and low (vessel walls, fat,
muscle) X-ray absorbing tissues present in the diseased artery. Tomography datasets
of the sample fixed in formalin and embedded in paraffin were recorded. After the
decalcification procedure and the re-embedding in paraffin, tomography data were
acquired in absorption contrast using both table-top laboratory and synchrotron ra-
diation sources. Tomography slices were compared to the histological counterparts.
Although the main features of the specimen were present both in tomography and
histology, some additional deformations due to histological sectioning could not be
avoided.
The results indicated that formalin fixation is the most appropriate procedure,
among the others here investigated, for imaging the specimen using µCT, as it
enabled localizing the plaque with reasonable precision. However, gas bubble for-
mation arising during the scan remains a crucial issue, that needs to be circumvented
in order to improve the quality of the lumen segmentation.
Microfluidics enabled mimicking a constricted blood vessel and SAXS provided ac-
cess to possible structural changes of Pad-PC-Pad liposomes when subjected to an
external perturbation. We report the successful detection of the liposomes within
the microfluidic device, despite the low lipid concentration achievable during the
preparation. The results indicated that Pad-PC-Pad liposomes subjected to shear
gradient modify their structure. This behavior was not observed in liposomes pre-
pared using DPPC phospholipid.
In this study, several shear rates have been tested, however only three of them have
been reported. Higher shear rates caused the formation of big air bubbles within
the microfluidic channel, which made the recorded data unusable. Further studies
should focus on improving the fabrication of the microfluidic device, e.g. strength
to higher flow rates.
The complex behavior of Pad-PC-Pad liposomes under flow conditions suggests
further efforts to fully understand their structural properties.
In the future, it would be advised to study dye-release by the liposomes exploiting
fluorescence microscopy and microchannels based on polydimethylsiloxane. Further-
more, it would be beneficial to investigate the membrane rigidity of the liposomes
by means of atomic force microscopy in liquid environment, an approach comple-
mentary to SAXS and microfluidics.
For the immediate treatment of arteries occlusion, Pad-PC-Pad liposomes are en-
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visioned for intravenous injection. The direct contact with human blood can result
in adverse immune reactions. CARPA is one of the most common safety issues
and reasons for nanomedicines failure. Therefore, the in vitro and in vivo tests
with Pad-PC-Pad liposomes were performed. Pad-PC-Pad liposomes loaded with
a vasodilatory drug and incubated in human sera and pig plasma might initiate
the complement cascade via the alternative pathway. The in vitro studies were
confirmed by the animal study where no significant changes, in the continuously
monitored hemodynamic parameters, were observed. Activation of the complement
system anaphylatoxins can also trigger cytokine-mediated inflammation. Conse-
quently, it would be advised to detect the impact of Pad-PC-Pad liposomes upon
activation of pro-inflammatory cytokines.
One limitation of the Pad-PC-Pad liposomes for applications within the human body
lies in the main phase transition temperature, which is very close to body temper-
ature. In fact, above 37◦C, Pad-PC-Pad liposomes release their cargo completely.
Consequently, for clinical use, it would be beneficial to develop more thermally stable
mechano-responsive nano-carriers than those discussed here.
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